UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ | Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the quarterly period ended September 30, 2021March 31, 2022
☐ | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Commission File No.: 000-27701
HealthStream, Inc.
(Exact name of registrant as specified in its charter)
Tennessee | 62-1443555 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
500 11th Avenue North, Suite 1000, | |
Nashville, Tennessee | 37203 |
(Address of principal executive offices) | (Zip Code) |
(615) 301-3100
(Registrant's telephone number, including area code)
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock (Par Value $0.00) | HSTM | Nasdaq Global Select Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | ||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | ||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of OctoberApril 25, 2021,2022, there were 31,562,19330,391,600 shares of the registrant’s common stock outstanding.
HEALTHSTREAM, INC.
Page Number | ||
Part I. | ||
Item 1. | ||
Notes to Condensed Consolidated Financial Statements (Unaudited) | ||
Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | |
Item 3. | ||
Item 4. | ||
Part II. | ||
Item 1A. | ||
Item 6. | ||
Item 1. Financial Statements
HEALTHSTREAM, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands)
September 30, | December 31, | March 31, | December 31, | |||||||||||||
2021 | 2020 | 2022 | 2021 | |||||||||||||
ASSETS | ||||||||||||||||
Current assets: | ||||||||||||||||
Cash and cash equivalents | $ | 55,459 | $ | 36,566 | $ | 43,370 | $ | 46,905 | ||||||||
Marketable securities | 5,095 | 9,928 | 2,008 | 5,041 | ||||||||||||
Accounts receivable, net of allowance for doubtful accounts of $408 and $549 at September 30, 2021 and December 31, 2020, respectively | 26,991 | 40,726 | ||||||||||||||
Accounts receivable, net of allowance for doubtful accounts of $541 and $853 at March 31, 2022 and December 31, 2021, respectively | 35,739 | 30,308 | ||||||||||||||
Accounts receivable - unbilled | 3,754 | 5,374 | 5,049 | 4,612 | ||||||||||||
Prepaid royalties, net of amortization | 9,733 | 9,571 | 11,188 | 9,155 | ||||||||||||
Other prepaid expenses and other current assets | 11,224 | 12,560 | 9,872 | 10,824 | ||||||||||||
Total current assets | 112,256 | 114,725 | 107,226 | 106,845 | ||||||||||||
Property and equipment, net of accumulated depreciation of $24,131 and $19,237 at September 30, 2021 and December 31, 2020, respectively | 18,333 | 22,218 | ||||||||||||||
Capitalized software development, net of accumulated amortization of $81,734 and $70,516 at September 30, 2021 and December 31, 2020, respectively | 31,250 | 26,631 | ||||||||||||||
Property and equipment, net of accumulated depreciation of $19,270 and $17,999 at March 31, 2022 and December 31, 2021, respectively | 17,070 | 17,950 | ||||||||||||||
Capitalized software development, net of accumulated amortization of $90,537 and $86,097 at March 31, 2022 and December 31, 2021, respectively | 34,131 | 32,412 | ||||||||||||||
Operating lease right of use assets, net | 25,869 | 28,081 | 24,589 | 25,168 | ||||||||||||
Goodwill | 181,114 | 178,440 | 182,785 | 182,501 | ||||||||||||
Customer-related intangibles, net of accumulated amortization of $43,362 and $36,723 at September 30, 2021 and December 31, 2020, respectively | 70,782 | 76,927 | ||||||||||||||
Other intangible assets, net of accumulated amortization of $15,431 and $10,748 at September 30, 2021 and December 31, 2020, respectively | 19,563 | 23,788 | ||||||||||||||
Customer-related intangibles, net of accumulated amortization of $47,847 and $45,615 at March 31, 2022 and December 31, 2021, respectively | 66,661 | 68,803 | ||||||||||||||
Other intangible assets, net of accumulated amortization of $18,140 and $16,752 at March 31, 2022 and December 31, 2021, respectively | 19,016 | 20,402 | ||||||||||||||
Deferred tax assets | 974 | 974 | 601 | 601 | ||||||||||||
Deferred commissions | 22,860 | 19,907 | 24,142 | 24,012 | ||||||||||||
Non-marketable equity investments | 8,338 | 6,845 | 6,767 | 7,043 | ||||||||||||
Other assets | 3,375 | 1,777 | 938 | 1,016 | ||||||||||||
Total assets | $ | 494,714 | $ | 500,313 | $ | 483,926 | $ | 486,753 | ||||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||
Current liabilities: | ||||||||||||||||
Accounts payable and accrued expenses | $ | 22,170 | $ | 29,457 | $ | 17,770 | $ | 21,497 | ||||||||
Accrued royalties | 5,203 | 8,809 | 6,914 | 5,037 | ||||||||||||
Deferred revenue | 74,577 | 81,176 | 89,878 | 73,816 | ||||||||||||
Total current liabilities | 101,950 | 119,442 | 114,562 | 100,350 | ||||||||||||
Deferred tax liabilities | 18,205 | 14,523 | 18,841 | 18,146 | ||||||||||||
Deferred revenue, noncurrent | 1,915 | 1,603 | 990 | 1,583 | ||||||||||||
Operating lease liability, noncurrent | 26,852 | 28,479 | 25,496 | 26,178 | ||||||||||||
Other long term liabilities | 3,594 | 2,204 | 1,465 | 1,477 | ||||||||||||
Commitments and contingencies | ||||||||||||||||
Shareholders’ equity: | ||||||||||||||||
Common stock, no par value, 75,000 shares authorized; 31,562 and 31,493 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively | 273,573 | 271,784 | ||||||||||||||
Common stock, no par value, 75,000 shares authorized; 30,518 and 31,327 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | 251,179 | 270,791 | ||||||||||||||
Retained earnings | 68,510 | 62,277 | 71,015 | 68,122 | ||||||||||||
Accumulated other comprehensive income | 115 | 1 | 378 | 106 | ||||||||||||
Total shareholders’ equity | 342,198 | 334,062 | 322,572 | 339,019 | ||||||||||||
Total liabilities and shareholders’ equity | $ | 494,714 | $ | 500,313 | $ | 483,926 | $ | 486,753 | ||||||||
See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(In thousands, except per share data)
Three Months Ended | Nine Months Ended | Three Months Ended | ||||||||||||||||||||||
September 30, 2021 | September 30, 2020 | September 30, 2021 | September 30, 2020 | March 31, 2022 | March 31, 2021 | |||||||||||||||||||
Revenues, net | $ | 64,091 | $ | 60,883 | $ | 192,374 | $ | 183,008 | $ | 65,367 | $ | 63,468 | ||||||||||||
Operating costs and expenses: | ||||||||||||||||||||||||
Cost of revenues (excluding depreciation and amortization) | 22,585 | 23,302 | 68,053 | 66,596 | 21,998 | 22,748 | ||||||||||||||||||
Product development | 10,344 | 8,192 | 30,205 | 23,491 | 10,412 | 9,525 | ||||||||||||||||||
Sales and marketing | 10,232 | 8,863 | 28,713 | 26,286 | 10,417 | 9,019 | ||||||||||||||||||
Other general and administrative expenses | 10,004 | 9,986 | 29,445 | 29,949 | 9,183 | 9,723 | ||||||||||||||||||
Depreciation and amortization | 9,141 | 7,406 | 27,443 | 22,005 | 9,322 | 9,153 | ||||||||||||||||||
Total operating costs and expenses | 62,306 | 57,749 | 183,859 | 168,327 | 61,332 | 60,168 | ||||||||||||||||||
Operating income | 1,785 | 3,134 | 8,515 | 14,681 | 4,035 | 3,300 | ||||||||||||||||||
Other (loss) income, net | (99 | ) | 100 | (250 | ) | 2,006 | ||||||||||||||||||
Other loss, net | (276 | ) | (87 | ) | ||||||||||||||||||||
Income before income tax provision | 1,686 | 3,234 | 8,265 | 16,687 | 3,759 | 3,213 | ||||||||||||||||||
Income tax provision | 186 | 600 | 2,033 | 3,519 | 866 | 922 | ||||||||||||||||||
Net income | $ | 1,500 | $ | 2,634 | $ | 6,232 | $ | 13,168 | $ | 2,893 | $ | 2,291 | ||||||||||||
Net income per share: | ||||||||||||||||||||||||
Basic | $ | 0.05 | $ | 0.08 | $ | 0.20 | $ | 0.41 | $ | 0.09 | $ | 0.07 | ||||||||||||
Diluted | $ | 0.05 | $ | 0.08 | $ | 0.20 | $ | 0.41 | $ | 0.09 | $ | 0.07 | ||||||||||||
Weighted average shares of common stock outstanding: | ||||||||||||||||||||||||
Basic | 31,558 | 31,955 | 31,538 | 32,095 | 30,955 | 31,504 | ||||||||||||||||||
Diluted | 31,684 | 31,981 | 31,609 | 32,121 | 30,976 | 31,526 | ||||||||||||||||||
See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
(In thousands)
Three Months Ended | Nine Months Ended | Three Months Ended | ||||||||||||||||||||||
September 30, 2021 | September 30, 2020 | September 30, 2021 | September 30, 2020 | March 31, 2022 | March 31, 2021 | |||||||||||||||||||
Net income | $ | 1,500 | $ | 2,634 | $ | 6,232 | $ | 13,168 | $ | 2,893 | $ | 2,291 | ||||||||||||
Other comprehensive income, net of taxes: | ||||||||||||||||||||||||
Foreign currency translation adjustments | (470 | ) | 23 | 107 | (4 | ) | 278 | 230 | ||||||||||||||||
Unrealized (loss) gain on marketable securities | (1 | ) | (18 | ) | 7 | 6 | (6 | ) | 4 | |||||||||||||||
Total other comprehensive (loss) income | (471 | ) | 5 | 114 | 2 | |||||||||||||||||||
Total other comprehensive income | 272 | 234 | ||||||||||||||||||||||
Comprehensive income | $ | 1,029 | $ | 2,639 | $ | 6,346 | $ | 13,170 | $ | 3,165 | $ | 2,525 | ||||||||||||
See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)
(In thousands)
Nine Months Ended September 30, 2021 | Three Months Ended March 31, 2022 | |||||||||||||||||||||||||||||||||||||||
Common Stock | Retained | Accumulated Other Comprehensive | Total Shareholders’ | Common Stock | Retained | Accumulated Other Comprehensive | Total Shareholders’ | |||||||||||||||||||||||||||||||||
Shares | Amount | Earnings | Income | Equity | Shares | Amount | Earnings | Income | Equity | |||||||||||||||||||||||||||||||
Balance at December 31, 2020 | 31,493 | $ | 271,784 | $ | 62,277 | $ | 1 | $ | 334,062 | |||||||||||||||||||||||||||||||
Balance at December 31, 2021 | 31,327 | $ | 270,791 | $ | 68,122 | $ | 106 | $ | 339,019 | |||||||||||||||||||||||||||||||
Net income | — | 0 | 2,291 | 0 | 2,291 | — | 0 | 2,893 | 0 | 2,893 | ||||||||||||||||||||||||||||||
Comprehensive income | — | 0 | 0 | 234 | 234 | — | 0 | 0 | 272 | 272 | ||||||||||||||||||||||||||||||
Stock based compensation | — | 616 | 0 | 0 | 616 | |||||||||||||||||||||||||||||||||||
Stock-based compensation | — | 774 | 0 | 0 | 774 | |||||||||||||||||||||||||||||||||||
Common stock issued under stock plans, net of shares withheld for employee taxes | 60 | (399 | ) | 0 | 0 | (399 | ) | 83 | (497 | ) | 0 | 0 | (498 | ) | ||||||||||||||||||||||||||
Balance at March 31, 2021 | 31,553 | $ | 272,001 | $ | 64,569 | $ | 235 | $ | 336,805 | |||||||||||||||||||||||||||||||
Net income | — | 0 | 2,441 | 0 | 2,441 | |||||||||||||||||||||||||||||||||||
Comprehensive income | — | 0 | 0 | 351 | 351 | |||||||||||||||||||||||||||||||||||
Stock based compensation | — | 782 | 0 | 0 | 782 | |||||||||||||||||||||||||||||||||||
Common stock issued under stock plans, net of shares withheld for employee taxes | 1 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 | 31,554 | $ | 272,783 | $ | 67,010 | $ | 586 | $ | 340,379 | |||||||||||||||||||||||||||||||
Net income | — | 0 | 1,500 | 0 | 1,500 | |||||||||||||||||||||||||||||||||||
Comprehensive loss | — | 0 | 0 | (471 | ) | (471 | ) | |||||||||||||||||||||||||||||||||
Stock based compensation | — | 862 | 0 | 0 | 862 | |||||||||||||||||||||||||||||||||||
Common stock issued under stock plans, net of shares withheld for employee taxes | 8 | (72 | ) | 0 | 0 | (72 | ) | |||||||||||||||||||||||||||||||||
Balance at September 30, 2021 | 31,562 | $ | 273,573 | $ | 68,510 | $ | 115 | $ | 342,198 | |||||||||||||||||||||||||||||||
Repurchase of common stock | (892 | ) | (19,889 | ) | 0 | 0 | (19,888 | ) | ||||||||||||||||||||||||||||||||
Balance at March 31, 2022 | 30,518 | $ | 251,179 | $ | 71,015 | $ | 378 | $ | 322,572 | |||||||||||||||||||||||||||||||
Three Months Ended March 31, 2021 | ||||||||||||||||||||
Common Stock | Retained | Accumulated Other Comprehensive | Total Shareholders’ | |||||||||||||||||
Shares | Amount | Earnings | Income | Equity | ||||||||||||||||
Balance at December 31, 2020 | 31,493 | $ | 271,784 | $ | 62,277 | $ | 1 | $ | 334,062 | |||||||||||
Net income | — | 0 | 2,291 | 0 | 2,291 | |||||||||||||||
Comprehensive income | — | 0 | 0 | 234 | 234 | |||||||||||||||
Stock-based compensation | — | 616 | 0 | 0 | 616 | |||||||||||||||
Common stock issued under stock plans, net of shares withheld for employee taxes | 60 | (399 | ) | 0 | 0 | (399 | ) | |||||||||||||
Balance at March 31, 2021 | 31,553 | $ | 272,001 | $ | 64,569 | $ | 235 | $ | 336,805 | |||||||||||
See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.
HEALTHSTREAM, INC.
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)
(In thousands)
Nine Months Ended September 30, 2020 | ||||||||||||||||||||
Common Stock | Retained | Accumulated Other Comprehensive | Total Shareholders’ | |||||||||||||||||
Shares | Amount | Earnings | Income (Loss) | Equity | ||||||||||||||||
Balance at December 31, 2019 | 32,379 | $ | 290,021 | $ | 48,143 | $ | 4 | $ | 338,168 | |||||||||||
Net income | — | 0 | 7,092 | 0 | 7,092 | |||||||||||||||
Comprehensive loss | — | 0 | 0 | (145 | ) | (145 | ) | |||||||||||||
Stock based compensation | — | 550 | 0 | 0 | 550 | |||||||||||||||
Common stock issued under stock plans, net of shares withheld for employee taxes | 62 | (373 | ) | 0 | 0 | (373 | ) | |||||||||||||
Repurchase of common stock | (438 | ) | (9,876 | ) | 0 | 0 | (9,876 | ) | ||||||||||||
Balance at March 31, 2020 | 32,003 | $ | 280,322 | $ | 55,235 | $ | (141 | ) | $ | 335,416 | ||||||||||
Net income | — | 0 | 3,442 | 0 | 3,442 | |||||||||||||||
Comprehensive income | — | 0 | 0 | 142 | 142 | |||||||||||||||
Stock based compensation | — | 557 | 0 | 0 | 557 | |||||||||||||||
Repurchase of common stock | (6 | ) | (133 | ) | 0 | 0 | (133 | ) | ||||||||||||
Balance at June 30, 2020 | 31,997 | $ | 280,746 | $ | 58,677 | $ | 1 | $ | 339,424 | |||||||||||
Net income | — | 0 | 2,634 | 0 | 2,634 | |||||||||||||||
Dividend forfeitures | — | 0 | 43 | 0 | 43 | |||||||||||||||
Comprehensive income | — | 0 | 0 | 5 | 5 | |||||||||||||||
Stock based compensation | — | 557 | 0 | 0 | 557 | |||||||||||||||
Common stock issued under stock plans, net of shares withheld for employee taxes | 8 | (55 | ) | 0 | 0 | (55 | ) | |||||||||||||
Repurchase of common stock | (319 | ) | (6,343 | ) | 0 | 0 | (6,343 | ) | ||||||||||||
Balance at September 30, 2020 | 31,686 | $ | 274,905 | $ | 61,354 | $ | 6 | $ | 336,265 | |||||||||||
See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
Nine Months Ended September 30, | Three Months Ended March 31, | |||||||||||||||
2021 | 2020 | 2022 | 2021 | |||||||||||||
OPERATING ACTIVITIES: | ||||||||||||||||
Net income | $ | 6,232 | $ | 13,168 | $ | 2,893 | $ | 2,291 | ||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||
Depreciation and amortization | 27,443 | 22,005 | 9,322 | 9,153 | ||||||||||||
Stock based compensation | 2,260 | 1,665 | ||||||||||||||
Stock-based compensation | 774 | 616 | ||||||||||||||
Amortization of deferred commissions | 6,900 | 6,555 | 2,484 | 2,133 | ||||||||||||
Provision for doubtful accounts | 99 | 160 | ||||||||||||||
Provision for credit losses | 6 | 142 | ||||||||||||||
Deferred income taxes | 2,066 | 2,330 | 684 | 486 | ||||||||||||
Loss on non-marketable equity investments | 258 | 8 | 276 | 54 | ||||||||||||
Non-cash paid time off expense | (1,011 | ) | 0 | 0 | (1,011 | ) | ||||||||||
Non-cash royalty expense | 0 | (3,440 | ) | |||||||||||||
Change in fair value of non-marketable equity investments | 0 | (1,181 | ) | |||||||||||||
Other | 132 | 321 | 26 | 15 | ||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||
Accounts and unbilled receivables | 13,907 | (9 | ) | (5,874 | ) | 7,379 | ||||||||||
Prepaid royalties | (162 | ) | 1,394 | (2,033 | ) | (2,215 | ) | |||||||||
Other prepaid expenses and other current assets | 1,335 | 972 | 952 | 2,521 | ||||||||||||
Deferred commissions | (9,854 | ) | (6,693 | ) | (2,614 | ) | (3,602 | ) | ||||||||
Other assets | (278 | ) | 308 | 79 | (76 | ) | ||||||||||
Accounts payable and accrued expenses | (3,062 | ) | (450 | ) | (3,653 | ) | (5,339 | ) | ||||||||
Accrued royalties | (3,606 | ) | (3,218 | ) | 1,877 | (305 | ) | |||||||||
Deferred revenue | (6,223 | ) | (3,142 | ) | 15,456 | 6,862 | ||||||||||
Net cash provided by operating activities | 36,436 | 30,753 | 20,655 | 19,104 | ||||||||||||
INVESTING ACTIVITIES: | ||||||||||||||||
Business combinations, net of cash acquired | (731 | ) | (21,449 | ) | (22 | ) | (731 | ) | ||||||||
Proceeds from maturities of marketable securities | 9,931 | 59,522 | 5,025 | 4,500 | ||||||||||||
Purchases of marketable securities | (5,223 | ) | (61,178 | ) | (2,024 | ) | (5,205 | ) | ||||||||
Payments to acquire non-marketable equity investments | 0 | (1,257 | ) | 0 | (1,000 | ) | ||||||||||
Payments to acquire equity method investments | (1,750 | ) | 0 | |||||||||||||
Payments associated with capitalized software development | (16,577 | ) | (12,366 | ) | (6,305 | ) | (5,326 | ) | ||||||||
Purchases of property and equipment | (2,602 | ) | (1,734 | ) | (636 | ) | (1,898 | ) | ||||||||
Net cash used in investing activities | (16,952 | ) | (38,462 | ) | (3,962 | ) | (9,660 | ) | ||||||||
FINANCING ACTIVITIES: | ||||||||||||||||
Taxes paid related to net settlement of equity awards | (471 | ) | (429 | ) | (497 | ) | (399 | ) | ||||||||
Repurchases of common stock | 0 | (16,352 | ) | (19,726 | ) | 0 | ||||||||||
Payment of cash dividends | (19 | ) | (40 | ) | 0 | (12 | ) | |||||||||
Net cash used in financing activities | (490 | ) | (16,821 | ) | (20,223 | ) | (411 | ) | ||||||||
Effect of exchange rate changes on cash and cash equivalents | (101 | ) | (1 | ) | (5 | ) | (251 | ) | ||||||||
Net increase (decrease) in cash and cash equivalents | 18,893 | (24,531 | ) | |||||||||||||
Net (decrease) increase in cash and cash equivalents | (3,535 | ) | 8,782 | |||||||||||||
Cash and cash equivalents at beginning of period | 36,566 | 131,538 | 46,905 | 36,566 | ||||||||||||
Cash and cash equivalents at end of period | $ | 55,459 | $ | 107,007 | $ | 43,370 | $ | 45,348 | ||||||||
SUPPLEMENTAL CASH FLOW INFORMATION: | ||||||||||||||||
Non-cash additions to non-marketable equity investments | $ | 0 | $ | 1,300 | ||||||||||||
See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. BASIS OF PRESENTATION
The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S‑X. Accordingly, condensed consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated in consolidation. Operating results for the three and ninemonths ended September 30, 2021March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.2022.
The Condensed Consolidated Balance Sheet at December 31, 20202021 was derived from the audited Consolidated Financial Statements at that date but does not include all of the information and footnotes required by US GAAP for a complete set of financial statements. For further information, refer to the Consolidated Financial Statements and Notes thereto for the year ended December 31, 20202021 (included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 25, 2021)28, 2022).
2. RECENT ACCOUNTING PRONOUNCEMENTS
Accounting Standards Recently Adopted
In October 2021, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") 2021-08,Business Combinations (Topic805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new guidance requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification ("ASC") 606,Revenue from Contracts with Customers, as if it had originated the contracts. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2022 and early adoption is permitted. The Company early adopted this ASU on January 1, 2022, and the adoption impact of the new standard will depend on the magnitude of future acquisitions. The standard will not impact contract assets or liabilities from business combinations that occurred prior to the adoption date.
3. REVENUE RECOGNITION AND SALES COMMISSIONS
Revenue Recognition
Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled in exchange for transferring those goods or services.
Revenue is recognized based on the following five step model:
• | Identification of the contract with a customer |
• | Identification of the performance obligations in the contract |
• | Determination of the transaction price |
• | Allocation of the transaction price to the performance obligations in the contract |
• | Recognition of revenue when, or as, the Company satisfies a performance obligation |
The following table represents revenues disaggregated by revenue source (in thousands). Sales taxes are excluded from revenues.
Three Months Ended September 30, 2021 | Nine Months Ended September 30, 2021 | |||||||||||||||||||||||
Business Segments | Workforce Solutions | Provider Solutions | Consolidated | Workforce Solutions | Provider Solutions | Consolidated | ||||||||||||||||||
Subscription services | $ | 49,729 | $ | 10,973 | $ | 60,702 | $ | 150,239 | $ | 32,475 | $ | 182,714 | ||||||||||||
Professional services | 1,426 | 1,963 | 3,389 | 4,320 | 5,340 | 9,660 | ||||||||||||||||||
Total revenues, net | $ | 51,155 | $ | 12,936 | $ | 64,091 | $ | 154,559 | $ | 37,815 | $ | 192,374 | ||||||||||||
Three Months Ended March 31, 2022 | ||||||||||||
| Workforce | Provider | Consolidated | |||||||||
Subscription services | $ | 50,553 | $ | 11,522 | $ | 62,075 | ||||||
Professional services | 1,486 | 1,806 | 3,292 | |||||||||
Total revenues, net | $ | 52,039 | $ | 13,328 | $ | 65,367 | ||||||
Three Months Ended March 31, 2021 | ||||||||||||
| Workforce | Provider | Consolidated | |||||||||
Subscription services | $ | 49,770 | $ | 10,597 | $ | 60,367 | ||||||
Professional services | 1,477 | 1,624 | 3,101 | |||||||||
Total revenues, net | $ | 51,247 | $ | 12,221 | $ | 63,468 | ||||||
Three Months Ended September 30, 2020 | Nine Months Ended September 30, 2020 | |||||||||||||||||||||||
Business Segments | Workforce Solutions | Provider Solutions | Consolidated | Workforce Solutions | Provider Solutions | Consolidated | ||||||||||||||||||
Subscription services | $ | 48,246 | $ | 9,999 | $ | 58,245 | $ | 144,945 | $ | 29,937 | $ | 174,882 | ||||||||||||
Professional services | 951 | 1,687 | 2,638 | 2,964 | 5,162 | 8,126 | ||||||||||||||||||
Total revenues, net | $ | 49,197 | $ | 11,686 | $ | 60,883 | $ | 147,909 | $ | 35,099 | $ | 183,008 | ||||||||||||
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
For the ninethree months ended September 30, 2021March 31, 2022 and 20202021, the Company recognized $0.1 million$6,000 and $0.2$0.1 million in impairment losses on receivables and contract assets arising from the Company’s contracts with customers, respectively.
Deferred revenue represents contract liabilities that are recorded when cash payments are received or are due in advance of our satisfaction of performance obligations. During the three months ended September 30, 2021March 31, 2022 and 20202021, we recognized revenues of approximately $39.4$34.6 million and $34.4$33.6 million, respectively, from amounts included in deferred revenue at the beginning of the respective periods. During the nine months ended September 30, 2021 and 2020, we recognized $59.3 million and $60.5 million of revenue from amounts included in deferred revenues at the beginning of the respective periods. As of September 30, 2021March 31, 2022, approximately $446$444 million of revenue is expected to be recognized from remaining performance obligations under contracts with customers. We expect to recognize revenue related to approximately 46%44% of these remaining performance obligations over the next 12 months, with the remaining amounts recognized thereafter.
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Sales Commissions
Sales commissions earned by our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Under ASC 606, costs to acquire contracts with customers, such as the initial sales commission payment and associated payroll taxes, are capitalized in the period a customer contract is entered into and are amortized consistent with the transfer of the goods or services to the customer over the expected period of benefit, whereas subsequent sales commission payments which require a substantive performance condition of the employee are expensed ratably through the payment date.benefit. Capitalized contract costs are included in deferred commissions in the accompanying Condensed Consolidated Balance Sheets. The expected period of benefit is the contract term, except when the capitalized commission is expected to provide economic benefit to the Company for a period longer than the contract term, such as for new customer or incremental sales where renewals are expected and renewal commissions are not commensurate with initial commissions. Non-commensurate commissions are amortized over the greater of the contract term or technological obsolescence period of approximately three years. The Company recorded amortization of deferred commissions of approximately $2.4$2.5 million and $2.3$2.1 million for the three months ended September 30, 2021March 31, 2022 and 2020, and $6.9 million and $6.6 million for the nine months ended September 30, 2021and 2020, respectively, which is included in sales and marketing expenses in the accompanying Condensed Consolidated Statements of Income.
3.4. INCOME TAXES
Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income.
The Company computes its interim period provision for income taxes by applying the estimated annual effective tax rate to year-to-date pretax income or loss and adjusts the provision for discrete tax items recorded in the period. During both the three months ended September 30, 2021March 31, 2022 and 20202021, the Company recorded a provision for income taxes of approximately $0.2 million and $0.6 million, respectively. During the nine months ended September 30, 2021 and 2020, the Company recorded a provision for income taxes of $2.0 million and $3.5 million, respectively.$0.9 million. The Company’s effective tax rate was 23% and 29% for the ninethree months ended September 30, 2021March 31, 2022 and 20202021 was 25% and 21%, respectively. The Company’s effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, foreign income taxes, and the effect of various permanent tax differences. The Company recognizes excess tax benefits and tax deficiencies associated with stock-based awards as a component of its provision for income taxes. During the ninethree months ended September 30,March 31, 2022, the Company recorded discrete tax expense of $0.1 million, which consisted primarily of tax deficiencies associated with stock-based awards. During the three months ended March 31, 2021, the Company recorded discrete tax expense of $0.2a $0.1 million which includedrelated primarily to a permanent difference related to purchase accounting adjustments changes inand the impact of a state tax ratesrate change enacted during the period, and lower research and development tax credits recognized than previously estimated. During the nine months ended September 30, 2020, the Company recorded a $1.2 million change in fair value of non-marketable equity investments as a result of the NurseGrid acquisition, which is not a taxable transaction, resulting in a tax benefit of $0.3 million, and recognized tax benefits resulting from higher research and development tax credits than previously estimated.period.
4.5. SHAREHOLDERS’ EQUITY
Stock BasedStock-Based Compensation
The Company has stock awards outstanding under its 2016 Omnibus Incentive Plan. The Company accounts for its stock basedstock-based compensation plan using the fair-value based method for costs related to share basedshare-based payments, including restricted share units (“RSUs”). and stock options. During the ninethree months ended September 30, 2021March 31, 2022, the Company issued 129,906approved the grant of 135,352 RSUs subject to service-based time vesting, of which 35,161 of these RSUs were conditioned upon and subject to shareholder approval of our 2022 Omnibus Incentive Plan to be submitted to the Company's shareholders for approval at the annual meeting of the Company's shareholders to be held on May 26, 2022. Of these, the 100,191 RSUs that were not conditioned on shareholder approval of our 2022 Omnibus Incentive Plan were granted with a weighted average grant date fair value of $23.44$20.32 per share, measured based on the closing fair market value of the Company’s stock on the date of grant. Applicable accounting standards require that the 35,161 RSUs conditioned upon approval of our 2022 Omnibus Incentive Plan not be valued unless and until the condition is met (that is, at such time that the 2022 Omnibus Incentive Plan is approved by shareholders at the annual meeting of the Company’s shareholders on May 26, 2022). During the ninethree months ended September 30, 2020March 31, 2021, the Company issued 114,784121,551 RSUs subject to service-based time vesting with a weighted average grant date fair value of $22.94$23.16 per share, measured based on the closing fair market value of the Company’s stock on the date of grant.
During the three months ended June 30, 2018, the Company granted 70,000 performance-based RSUs, the vesting of which occurs over a five-year period and is contingent upon continued service and achieving certain performance criteria established by the Compensation Committee on an annual basis in increments of 10%, 15%, 20%, 25%, and 30% based on performance in 2018,2019,2020,2021, and 2022, respectively. The performance criteria for the final 21,000 of these performance-based RSUs is based on 2022 performance. The measurement date for these 21,000 performance-based RSUs was established during the three months ended March 31, 2022 with a grant date fair value of $20.32 per share, measured based on the closing fair market value of the Company's stock on the date the performance criteria was established.
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
During the three months ended March 31,2022, the Company approved the grant of 91,042 performance-based RSUs, the vesting of which occurs over a five-year period and is contingent upon continued service and achieving certain performance criteria established by the Compensation Committee on an annual basis in increments of 15%, 20%, 20%, 20%, and 25% based on performance in 2022,2023,2024,2025, and 2026, respectively, of which 17,224 performance-based RSUs were conditioned upon and subject to shareholder approval of our 2022 Omnibus Incentive Plan to be submitted to the Company’s shareholders for approval at the annual meeting of the Company’s shareholders on May 26, 2022. Of the total amount of performance-based RSUs approved by the Company, the performance criteria for 13,654 of these performance-based RSUs is based on 2022 performance. The measurement date for the 11,070 of these performance-based RSUs that are not conditioned on approval of the 2022 Omnibus Incentive Plan at the annual meeting of shareholders on May 26, 2022 was established during the three months ended March 31, 2022 with a grant date fair value of $20.32 per share, measured based on the closing fair market value of the Company's stock on the date the performance criteria was established. Applicable accounting standards require that the 17,224 performance-based RSUs conditioned upon approval of our 2022 Omnibus Incentive Plan (including 2,584 of these performance-based RSUs for which performance criteria will be based on 2022 performance) not be valued unless and until the condition is met (that is, at such time that the 2022 Omnibus Incentive Plan is approved by shareholders at the annual meeting of the Company’s shareholders on May 26, 2022). The performance criteria for the remaining 77,388 performance-based RSUs with performance not based on 2022 performance has not yet been determined and will be established on an annual basis in 2023,2024,2025, and 2026, as applicable; therefore, the measurement date for these remaining 77,388 performance-based RSUs cannot be determined until the performance criteria have been established.
Total stock basedstock-based compensation expense recognized in the Condensed Consolidated Statements of Income is as follows (in thousands):
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Cost of revenues (excluding depreciation and amortization) | $ | 31 | $ | 16 | $ | 82 | $ | 39 | ||||||||
Product development | 111 | 92 | 329 | 266 | ||||||||||||
Sales and marketing | 76 | 60 | 217 | 170 | ||||||||||||
Other general and administrative | 644 | 389 | 1,632 | 1,190 | ||||||||||||
Total stock based compensation expense | $ | 862 | $ | 557 | $ | 2,260 | $ | 1,665 | ||||||||
Three Months Ended March 31, | ||||||||
2022 | 2021 | |||||||
Cost of revenues (excluding depreciation and amortization) | $ | 38 | $ | 20 | ||||
Product development | 125 | 102 | ||||||
Sales and marketing | 83 | 65 | ||||||
Other general and administrative | 528 | 429 | ||||||
Total stock based compensation expense | $ | 774 | $ | 616 | ||||
Share Repurchase Plan
On 8November 30, 2021,
Directors authorized a share repurchase program to repurchase up to $20.0 million of the Company's outstanding shares of common stock. This share repurchase program concluded on March 8, 2022, when the maximum dollar amount authorized under the program was expended. Under this program, the Company repurchased a total of 853,023 shares through open market purchases at an aggregate value of $20.0 million, reflecting an average price per share of $23.45 (excluding the cost of broker commissions). During the three months ended March 31, 2022, the Company repurchased 649,739 shares pursuant to this share repurchase program at an aggregate fair value of $14.9 million, based on an average price per share of $22.92 (excluding the cost of broker commissions).
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
On March 14, 2022, the Company's Board of Directors approved an expansion of the Company's share repurchase program by authorizing the repurchase of up to an additional $10.0 million of the Company's outstanding shares of common stock. The share repurchase expansion program will terminate on the earlier of March 13, 2023, or when the maximum dollar amount has been expended. During the three months ended March 31, 2022, the Company repurchased 242,647 shares pursuant to this share repurchase program at an aggregate fair value of $5.0 million, based on an average price per share of $20.52 (excluding the cost of broker commissions).
5.6. EARNINGS PER SHARE
Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of potentially dilutive common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and RSUs subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. The total number of common equivalent shares excluded from the calculations of diluted earnings per share, due to their anti-dilutive effect or contingent performance conditions, was approximately 26,000218,000 and 115,000148,000 for the three months ended September 30, 2021March 31, 2022 and 2020, respectively, and 95,000 and 112,000 for the nine months ended September 30, 2021and 2020, respectively.
The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share data):
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Numerator: | ||||||||||||||||
Net income | $ | 1,500 | $ | 2,634 | $ | 6,232 | $ | 13,168 | ||||||||
Denominator: | ||||||||||||||||
Weighted-average shares outstanding | 31,558 | 31,955 | 31,538 | 32,095 | ||||||||||||
Effect of dilutive shares | 126 | 26 | 71 | 26 | ||||||||||||
Weighted-average diluted shares | 31,684 | 31,981 | 31,609 | 32,121 | ||||||||||||
Net income per share: | ||||||||||||||||
Basic | $ | 0.05 | $ | 0.08 | $ | 0.20 | $ | 0.41 | ||||||||
Diluted | $ | 0.05 | $ | 0.08 | $ | 0.20 | $ | 0.41 |
| |||||||
Three Months Ended March 31, | ||||||||
2022 | 2021 | |||||||
Numerator: | ||||||||
Net income | $ | 2,893 | $ | 2,291 | ||||
Denominator: | ||||||||
Weighted-average shares outstanding | 30,955 | 31,504 | ||||||
Effect of dilutive shares | 21 | 22 | ||||||
Weighted-average diluted shares | 30,976 | 31,526 | ||||||
Net income per share: | ||||||||
Basic | $ | 0.09 | $ | 0.07 | ||||
Diluted | $ | 0.09 | $ | 0.07 | ||||
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
6.7. MARKETABLE SECURITIES
The fair value of marketable securities, which were all classified as available for sale and which the Company does not intend to sell nor will the Company be required to sell prior to recovery of their amortized cost basis, included the following (in thousands):
September 30, 2021 | ||||||||||||||||||||||||
Adjusted Cost | Unrealized Gains | Unrealized Losses | Fair Value | Cash and Cash Equivalents | Current Marketable Securities | |||||||||||||||||||
Cash | $ | 55,459 | $ | 0 | $ | 0 | $ | 55,459 | $ | 55,459 | $ | 0 | ||||||||||||
Level 2: | ||||||||||||||||||||||||
Corporate debt securities | 5,096 | 0 | (1 | ) | 5,095 | 0 | 5,095 | |||||||||||||||||
Total | $ | 60,555 | $ | 0 | $ | (1 | ) | $ | 60,554 | $ | 55,459 | $ | 5,095 | |||||||||||
December 31, 2020 | ||||||||||||||||||||||||
Adjusted | Unrealized | Unrealized | Fair Value | Cash and Cash Equivalents | Current Marketable Securities | |||||||||||||||||||
Cash | $ | 31,558 | $ | 0 | $ | 0 | $ | 31,558 | $ | 31,558 | $ | 0 | ||||||||||||
Level 2: | ||||||||||||||||||||||||
Time deposits | 10,021 | 0 | 0 | 10,021 | 5,008 | 5,013 | ||||||||||||||||||
Corporate debt securities | 4,923 | 0 | (8 | ) | 4,915 | 0 | 4,915 | |||||||||||||||||
Total | $ | 46,502 | $ | 0 | $ | (8 | ) | $ | 46,494 | $ | 36,566 | $ | 9,928 | |||||||||||
March 31, 2022 | ||||||||||||||||
Adjusted | Unrealized | Unrealized | Fair Value | |||||||||||||
Level 2: | ||||||||||||||||
Corporate debt securities | $ | 2,016 | $ | 0 | $ | (8 | ) | $ | 2,008 | |||||||
Total | $ | 2,016 | $ | 0 | $ | (8 | ) | $ | 2,008 | |||||||
December 31, 2021 | ||||||||||||||||
Adjusted | Unrealized | Unrealized | Fair Value | |||||||||||||
Level 2: | ||||||||||||||||
Corporate debt securities | $ | 5,043 | $ | 0 | $ | (2 | ) | $ | 5,041 | |||||||
Total | $ | 5,043 | $ | 0 | $ | (2 | ) | $ | 5,041 | |||||||
The carrying amounts reported in the Condensed Consolidated Balance Sheets approximate the fair value based on quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of September 30, 2021March 31, 2022, the Company did not recognize any allowance for credit impairments on its available for sale debt securities. All investments in marketable securities are classified as current assets on the Condensed Consolidated Balance Sheets because the underlying securities mature within one year from the balance sheet date.
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
7. BUSINESS COMBINATIONS
NurseGrid
On March 9, 2020, the Company acquired all of the outstanding stock of HcT2 Co. dba NurseGrid (“NurseGrid”), a Portland, Oregon-based healthcare technology company offering NurseGrid Mobile and its corollary application for nurse managers, NurseGrid Enterprise, for net cash consideration of approximately $21.5 million, after giving effect to the post-closing working capital adjustment. The Company accounted for this transaction as a business combination achieved in stages which required the Company to remeasure its previously existing minority ownership interest, which was accounted for as a non-marketable equity investment measured using the fair value alternative, to fair value at the acquisition date based on the total enterprise value, adjusting for a control premium. The fair value of the Company’s interest in NurseGrid was $3.6 million at closing, resulting in a gain of $1.2 million, recorded as a change in fair value of non-marketable equity investments in the Company’s Condensed Consolidated Statement of Income during the three months ended March 31, 2020. Additionally, the Company’s previously recorded non-marketable equity investment in NurseGrid was de-recognized from the Company’s Condensed Consolidated Balance Sheet during the same period. Acquisition-related transaction costs were $0.2 million. The financial results of NurseGrid have been included in the Workforce Solutions segment from March 9, 2020.
A summary of the purchase price is as follows (in thousands):
Cash paid at closing | $ | 25,485 | ||
Post-closing adjustment, net of cash received | 33 | |||
Cash acquired | (4,064 | ) | ||
Net consideration paid | 21,454 | |||
Fair value of existing equity interest in NurseGrid | 3,623 | |||
Net consideration paid | $ | 25,077 |
The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):
Accounts and unbilled receivable, net | $ | 92 | ||
Prepaid and other current assets | 155 | |||
Operating lease right-of-use assets | 50 | |||
Deferred tax assets | 2,121 | |||
Goodwill | 21,085 | |||
Intangible assets | 1,845 | |||
Accounts payable and accrued liabilities | (143 | ) | ||
Deferred revenue | (78 | ) | ||
Operating lease liabilities | (50 | ) | ||
Net assets acquired | $ | 25,077 |
The excess of purchase price over the fair values of net tangible and intangible assets is recorded as goodwill. The fair values of tangible and identifiable intangible assets and liabilities are based on management’s estimates and assumptions. The primary intangible assets acquired were developed technology and trade name. The fair value estimate for developed technology intangible asset included significant assumptions, including the estimate of employee hours that would be needed to recreate the technology. The fair value estimate for trade name intangible asset included significant assumptions in the prospective financial information, such as projected revenues, royalty rate, and the discount rate. Additionally, these assumptions are forward looking and could be affected by future economic and market conditions. The goodwill balance is primarily attributed to the assembled workforce, future market opportunities to engage and support the NurseGrid Mobile user community, and expected synergies from integrating NurseGrid with other combined functional areas within the Company. The goodwill balance is not deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $157,000 to an estimated fair value of $78,000. The $79,000 write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.
The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):
Fair value | Useful life (in years) | |||||||
Customer relationships | $ | 35 | 8 | |||||
Developed technology | 1,110 | 5 | ||||||
Trade name | 700 | Indefinite | ||||||
Total intangible assets | $ | 1,845 | ||||||
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
The following unaudited pro forma financial information summarizes the results of operations of the Company and NurseGrid as though the companies were combined as of January 1, 2019 (in thousands, except per share data):
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Total revenues | $ | 64,091 | $ | 60,900 | $ | 192,379 | $ | 183,133 | ||||||||
Net income | $ | 1,500 | $ | 2,648 | $ | 6,236 | $ | 12,632 | ||||||||
Net income per share - basic | $ | 0.05 | $ | 0.08 | $ | 0.20 | $ | 0.39 | ||||||||
Net income per share - diluted | $ | 0.05 | $ | 0.08 | $ | 0.20 | $ | 0.39 | ||||||||
These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition, such as amortization of intangible assets, depreciation of property and equipment, interest expense related to NurseGrid’s previously outstanding debt, and fair value adjustments of acquired deferred revenue balances. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company’s results of operations would have been had the transaction occurred at the beginning of the earliest period presented or to project the Company’s results of operations in any future period.
ShiftWizard
On October 12, 2020, the Company acquired all of the outstanding stock of ShiftWizard, Inc., a Raleigh, North Carolina-based healthcare technology company offering a SaaS-based solution that integrates key workforce management capabilities, including scheduling, productivity, and forecasting. The consideration paid for ShiftWizard consisted of $30.5 million in cash after giving effect to the post-closing working capital adjustment. Acquisition-related transaction costs were $0.3 million. The financial results of ShiftWizard have been included in the Workforce Solutions segment from October 12, 2020.
The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):
Cash | $ | 1,091 | ||
Accounts and unbilled receivable, net | 1,038 | |||
Prepaid assets | 106 | |||
Operating lease right-of-use assets | 183 | |||
Property and equipment | 50 | |||
Indemnification assets | 464 | |||
Goodwill | 19,307 | |||
Intangible asset | 12,660 | |||
Accounts payable and accrued liabilities | (600 | ) | ||
Deferred revenue | (1,601 | ) | ||
Deferred tax liability | (1,559 | ) | ||
Operating lease liabilities | (183 | ) | ||
Indemnification liability | (464 | ) | ||
Net assets acquired | $ | 30,492 |
The excess of purchase price over the fair values of net tangible and intangible assets is recorded as goodwill. The fair values of tangible and identifiable intangible assets and liabilities are based on management’s estimates and assumptions. Included in the assets and liabilities is an indemnification asset and liability of $0.5 million associated with a Paycheck Protection Program loan pending forgiveness as of the acquisition date that was subsequently forgiven. The primary intangible assets acquired were customer relationships and developed technology. The fair value estimate for customer relationships intangible asset included significant assumptions in the prospective financial information, such as revenue growth, customer attrition, EBITDA margin, and the discount rate. The fair value estimate for developed technology intangible asset included significant assumptions, including the estimate of employee hours that would be needed to recreate the technology. Additionally, these assumptions are forward looking and could be affected by future economic and market conditions. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering ShiftWizard products, and expected synergies from integrating ShiftWizard with other products or other combined functional areas within the Company. The goodwill balance is not deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $2.7 million to an estimated fair value of $1.6 million. The $1.1 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):
Fair Value | Useful life (in years) | |||||||
Customer relationships | $ | 7,800 | 18 | |||||
Developed technology | 4,050 | 5 | ||||||
Non-compete | 580 | 1 - 5 | ||||||
Trade name | 230 | 5 | ||||||
Total intangible assets | $ | 12,660 | ||||||
The following unaudited pro forma financial information summarizes the results of operations of the Company and ShiftWizard as though the companies were combined as of January 1, 2019 (in thousands, except per share data):
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Total revenues | $ | 64,210 | $ | 61,930 | $ | 192,910 | $ | 186,049 | ||||||||
Net income | $ | 1,615 | $ | 2,169 | $ | 6,690 | $ | 11,985 | ||||||||
Net income per share - basic | $ | 0.05 | $ | 0.07 | $ | 0.21 | $ | 0.37 | ||||||||
Net income per share - diluted | $ | 0.05 | $ | 0.07 | $ | 0.21 | $ | 0.37 | ||||||||
These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition, such as amortization of intangible assets, depreciation of property and equipment, and fair value adjustments of acquired deferred revenue balances. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company’s results of operations would have been had the transaction occurred at the beginning of the earliest period presented or to project the Company’s results of operations in any future period.
ANSOS™Staff Scheduling application
On December 2, 2020, the Company acquired all of the equity interests of Change Healthcare’s staff scheduling business, consisting of the ANSOS™ Staff Scheduling application and related products (ANSOS). The consideration paid for ANSOS was $66.4 million in cash, after giving effect to the post-closing working capital adjustment. Acquisition-related transaction costs were $1.2 million. The financial results of ANSOS have been included in the Workforce Solutions segment from December 2, 2020.
The following table summarizes the preliminary fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):
Cash | $ | 1,599 | ||
Accounts and unbilled receivable, net | 10,099 | |||
Prepaid assets | 233 | |||
Operating lease right-of-use assets | 888 | |||
Property and equipment | 66 | |||
Deferred tax assets | 2,855 | |||
Indemnification asset | 2,029 | |||
Goodwill | 36,748 | |||
Intangible assets | 32,440 | |||
Accounts payable and accrued liabilities | (1,776 | ) | ||
Deferred revenue | (14,204 | ) | ||
Operating lease liabilities | (888 | ) | ||
Deferred tax liability | (1,612 | ) | ||
Uncertain tax position liability | (2,029 | ) | ||
Net assets acquired | $ | 66,448 |
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
The excess of purchase price over the preliminary fair values of net tangible and intangible assets is recorded as goodwill. The fair values of tangible and identifiable intangible assets and liabilities are based on management’s estimates and assumptions. The preliminary fair values of assets acquired and liabilities assumed continue to be subject to change during the measurement period (up to one year from the acquisition date) as the Company finalizes the valuation of these items. The primary areas of the preliminary purchase price allocation that are not finalized include the composition and valuation of income tax attributes and working capital accounts. Included in the preliminary assets and liabilities acquired is an indemnification asset and an uncertain tax position liability determined based on management’s estimate of the most likely value related to income tax attributes. During the nine months ended September 30, 2021, the Company made adjustments to accounts receivable, deferred revenue, indemnification asset, uncertain tax position liability, accounts payable and accrued liabilities, and deferred tax assets based on updated information obtained since our preliminary estimates were made. As a result of these items, coupled with the impact of the post-closing working capital adjustment, the Company recorded a measurement period adjustment which increased goodwill by $1.5 million. The measurement period adjustment had no effect on current or prior period earnings. The primary intangible assets acquired were customer relationships and developed technology. The fair value estimate for customer relationships intangible asset included significant assumptions regarding prospective financial information with respect to the acquisition, including with respect to revenue growth, customer attrition, EBITDA margin, and the discount rate. The fair value estimate for developed technology intangible asset included significant assumptions, including the estimate of employee hours that would be needed to recreate the technology. Additionally, these assumptions are forward looking and could be affected by future economic and market conditions. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering ANSOS products, and expected synergies from integrating ANSOS with other products or other combined functional areas within the Company.
The portion of goodwill allocated to the U.S. entity is deductible for U.S. income tax purposes (representing 95%). The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $17.5 million to an estimated fair value of $14.2 million. The $3.3 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.
The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):
Fair Value | Useful life (in years) | |||||||
Customer relationships | $ | 21,100 | 11 - 14 | |||||
Developed technology | 9,800 | 5 | ||||||
Trade name | 1,540 | 10 | ||||||
Total intangible assets | $ | 32,440 | ||||||
The following unaudited pro forma financial information summarizes the results of operations of the Company and ANSOS as though the companies were combined as of January 1, 2019 (in thousands, except per share data):
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Total revenues | $ | 64,636 | $ | 66,924 | $ | 194,856 | $ | 203,129 | ||||||||
Net income | $ | 1,965 | $ | 3,407 | $ | 8,190 | $ | 16,514 | ||||||||
Net income per share - basic | $ | 0.06 | $ | 0.11 | $ | 0.26 | $ | 0.51 | ||||||||
Net income per share - diluted | $ | 0.06 | $ | 0.11 | $ | 0.26 | $ | 0.51 | ||||||||
These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition, such as amortization of intangible assets, depreciation of property and equipment, and fair value adjustments of acquired deferred revenue balances. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company’s results of operations would have been had the transaction occurred at the beginning of the earliest period presented or to project the Company’s results of operations in any future period.
Other Business Combinations
On December 10, 2020, the Company acquired substantially all of the assets of myClinicalExchange, LLC, a Denver, Colorado-based information technologies company offering a SaaS-based solution that allows healthcare organizations to track, manage, and report the intern and clinical rotation educational requirements of medical, nursing, and allied healthcare students as well as host required documentation for medical residents. The consideration paid for myClinicalExchange consisted of $4.4 million in cash. Acquisition-related transaction costs were $0.1 million. The acquisition is not considered material to the Company’s Financial Statements. The Company accounted for the acquisition as a business combination and has allocated the purchase consideration based on management’s estimates of fair value. The results of operations for myClinicalExchange are included in the Company’s Condensed Consolidated Financial Statements from the date of acquisition and are included in the Workforce Solutions segment.
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
On January 19, 2021, the Company acquired the issued and outstanding equity of ProcessDATA, Ltd. (d/b/a ComplyALIGN and HospitalPORTAL) (“ComplyALIGN”), a Chicago, Illinois-based healthcare technology company offering a SaaS-based policy management system for healthcare organizations, for $2.0 million in cash. The acquisition is not considered material to the Company’s financial statements. The Company accounted for the acquisition as a business combination and has allocated the purchase consideration based on management’s estimates of fair value. Acquisition-related transaction costs were $0.1 million. The results of operations for ComplyALIGN are included in the Company’s Condensed Consolidated Financial Statements from the date of acquisition and are included in the Workforce Solutions segment.
During the nine months ended September 30, 2021, the carrying amount of goodwill increased by $2.7 million, consisting of a $1.5 million of measurement period adjustment related to ANSOS, $1.0 million of acquired goodwill related to ComplyALIGN, and $0.2 million for the effect of currency translation adjustments.
8. BUSINESS SEGMENTS
The Company provides services to healthcare organizations and other members within the healthcare industry. The Company’s services are focused on the delivery of workforce training, certification, assessment, development, and scheduling products and services (Workforce Solutions) and provider credentialing, privileging, call center, and enrollment products and services (Provider Solutions).
The Company measures segment performance based on operating income before income taxes and prior to the allocation of certain corporate overhead expenses, interest income, interest expense, gains and losses from equity investments, and depreciation. The Unallocated component below includes corporate functions, such as accounting, human resources, legal, investor relations, information systems, administrative and executive personnel, depreciation, a portion of amortization, and certain other expenses, which are not currently allocated in measuring segment performance. The following is the Company’s business segment information (in thousands).
Three Months Ended September 30, | Nine Months Ended September 30, | Three Months Ended March 31, | ||||||||||||||||||||||
Revenues, net: | 2021 | 2020 | 2021 | 2020 | 2022 | 2021 | ||||||||||||||||||
Workforce Solutions | $ | 51,155 | $ | 49,197 | $ | 154,559 | $ | 147,909 | $ | 52,039 | $ | 51,247 | ||||||||||||
Provider Solutions | 12,936 | 11,686 | 37,815 | 35,099 | 13,328 | 12,221 | ||||||||||||||||||
Total revenues, net | $ | 64,091 | $ | 60,883 | $ | 192,374 | $ | 183,008 | $ | 65,367 | $ | 63,468 | ||||||||||||
Operating income: | ||||||||||||||||||||||||
Workforce Solutions | $ | 7,732 | $ | 9,758 | $ | 25,981 | $ | 33,575 | $ | 9,385 | $ | 9,224 | ||||||||||||
Provider Solutions | 1,974 | 913 | 6,195 | 3,382 | 2,311 | 1,858 | ||||||||||||||||||
Unallocated | (7,921 | ) | (7,537 | ) | (23,661 | ) | (22,276 | ) | (7,661 | ) | (7,782 | ) | ||||||||||||
Total operating income | $ | 1,785 | $ | 3,134 | $ | 8,515 | $ | 14,681 | $ | 4,035 | $ | 3,300 | ||||||||||||
Segment assets * | September 30, 2021 | December 31, 2020 | March 31, 2022 | December 31, 2021 | ||||||||||||
Workforce Solutions | $ | 259,036 | $ | 270,924 | $ | 266,882 | $ | 258,864 | ||||||||
Provider Solutions | 134,793 | 140,490 | 133,867 | 137,008 | ||||||||||||
Unallocated | 100,885 | 88,899 | 83,177 | 90,881 | ||||||||||||
Total assets | $ | 494,714 | $ | 500,313 | $ | 483,926 | $ | 486,753 | ||||||||
* | Segment assets include accounts and unbilled receivables, prepaid royalties, prepaid and other current assets, other assets, capitalized software development, deferred commissions, certain property and equipment, goodwill, and intangible assets. Cash and cash equivalents, marketable securities, non-marketable equity investments, and certain ROU assets are not allocated to individual segments and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated. |
HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
9. DEBT
Revolving Credit Facility
On October 28, 2020, the Company entered into a Third Amendment to Revolving Credit Agreement (Revolving Credit Facility), amending the Revolving Credit Facility dated as of November 24, 2014 with Truist Bank, successor by merger to SunTrust Bank (Truist), extending the maturity date to October 28, 2023. Under the Revolving Credit Facility, the Company may borrow up to $65.0 million, which includes a $5.0 million swing line sub-facility and a $5.0 million letter of credit sub-facility, as well as an accordion feature that allows the Company to increase the Revolving Credit Facility by a total of up to $25.0 million, subject to securing additional commitments from existing lenders or new lending institutions.
At the Company’s election, the borrowings under the Revolving Credit Facility bear interest at either (1) a rate per annum equal to the highest of Truist’s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the Base Rate), plus an applicable margin, or (2) the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the Eurocurrency Rate), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company’s funded debt leverage ratio and varies from 1.50% to 1.75%. The applicable margin for Base Rate loans depends on the Company’s funded debt leverage ratio and varies from 0.50% to 0.75%. Commitment fees and letter of credit fees are also payable under the Revolving Credit Facility. Principal is payable in full at maturity on October 28, 2023, and there are no scheduled principal payments prior to maturity. The Company is required to pay a commitment fee ranging between 20 and 30 basis points per annum of the average daily unused portion of the Revolving Credit Facility, depending on the Company’s funded debt leverage ratio. The obligations under the Revolving Credit Facility are guaranteed by each of the Company’s subsidiaries.
The purpose of the Revolving Credit Facility is for general working capital needs, permitted acquisitions (as defined in the Revolving Credit Facility), and for stock repurchase and/or redemption transactions that the Company may authorize.
The Revolving Credit Facility contains certain covenants that, among other things, restrict additional indebtedness, liens and encumbrances, changes to the character of the Company’s business, acquisitions, asset dispositions, mergers and consolidations, sale or discount of receivables, creation or acquisitions of additional subsidiaries, and other matters customarily restricted in such agreements.
In addition, the Revolving Credit Facility requires the Company to meet certain financial tests, including, without limitation:
• | a funded debt leverage ratio (consolidated debt/consolidated EBITDA) of not greater than 3.0 to 1.0; and |
• | an interest coverage ratio (consolidated EBITDA/consolidated interest expense) of not less than 3.0 to 1.0. |
As of September 30, 2021March 31, 2022, the Company was in compliance with all covenants. There were no balances outstanding on the Revolving Credit Facility as of or during the three and ninemonths ended September 30, 2021March 31, 2022.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Special Cautionary Notice Regarding Forward‑Looking Statements
You should read the following discussion and analysis in conjunction with our Condensed Consolidated Financial Statements and related Notes included elsewhere in this report and our audited Consolidated Financial Statements and the Notes thereto for the year ended December 31, 2020,2021, appearing in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (“SEC”) on February 25, 202128, 2022 (the “2020“2021 Form 10-K”). Statements contained in this Quarterly Report on Form 10-Q that are not historical facts are forward-looking statements that the Company intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Statements that are predictive in nature, that depend on or refer to future events or conditions, or that include words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions are forward-looking statements.
The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
In evaluating any forward-looking statement, you should specifically consider the information regarding forward-looking statements set forth above and the risks set forth under the caption Part I, Item 1A. Risk Factors in our 20202021 Form 10-K and other disclosures in our 20202021 Form 10-K, earnings releases and other filings with the SEC from time to time, as well as other cautionary statements contained elsewhere in this report, including our critical accounting policies and estimates as discussed in this report and our 20202021 Form 10-K. We undertake no obligation to update or revise any forward-looking statements. You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we currently expect.
Business Overview
HealthStream provides workforce and provider solutionsprimarily SaaS based applications for healthcare organizations—all designed to support the people that deliver patient care, which, in turn, supports the improvement ofimprove business and clinical outcomes by supporting the people who deliver patient care.
We are in the process of more completely unifying the Company under a single platform strategy that will serve as the foundation for the entire enterprise. By enabling our applications through a common technology platform known as hStream, we believe that stand-alone applications, which already provide a powerful value proposition, will begin to leverage each other to more efficiently and effectively empower our customers to manage their businesses and improve their outcomes. Our solutions includeAs we continue to achieve this goal of orienting multiple Software-as-a-Service (SaaS) applications in relation to a single technology platform, distinctions between our current reporting segments of Workforce Solutions and focusProvider Solutions may become less applicable, or even obsolete, in terms of how we operate and report on some of the most significant challenges facingCompany's business. At the healthcare workforcecurrent time, what we characterize and report on as Workforce Solutions products are used by healthcare organizations today, including the need to effectively manage, retain, engage, schedule,meet a broad range of their clinical development, learning and developperformance, certification, scheduling, safety and compliance, and competency assessment needs. Provider Solutions products are used by healthcare workforce talent; meet rigorous compliance requirements;organizations for provider credentialing, privileging, and efficiently manage ongoing medical staff credentialing and privileging processes.enrollment needs. HealthStream’s primary customers include healthcare organizations pharmaceutical and medical device companies, and other participants in the healthcare industry. At September 30, 2021, we had approximately 4.92 million contracted subscriptions to hStreamTM, our Platform-as-a-Service technology. hStream technology enables healthcare organizations and their respective workforces to easily connect to and gain value from the growing HealthStream ecosystem of applications, tools, and content.
Significant financial metrics for the thirdfirst quarter of 20212022 are set forth in the bullets below.
• | Revenues of |
• | Operating income of |
• | Net income of |
• | Earnings per share (“EPS”) of |
• | Adjusted EBITDA1 of
|
1 | Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this report. |
Impact of and Response to COVID-19 Pandemic
TheWhile the COVID-19 pandemic which spread throughoutpersists and remains a cause of uncertainty and potential volatility, conditions related to the world and the United States during 2020, resulted in a significant economic downturn. As vaccines have become widely available in the United States, economic conditionspandemic have generally improved in 2021 compared to 2020. However, during the third quarter of 2021, the number of COVID-19 cases and hospitalizations increased in the United States in comparisonrecent months, with the number of daily hospitalizations in the United States reaching a pandemic-era low during this period according to earlier levelsthe Centers for Disease Control and Prevention. In general, this means that the healthcare organizations we serve are no longer under the immediate threat of having their operations overrun by an overwhelming influx of COVID patients. As the inflow of COVID patients with respect to healthcare organizations has become more manageable, certain areas of our business, such as a resultour compliance and learning solutions, have begun to return to and, in some cases, even eclipse pre-pandemic norms. However, other parts of our business have continued to be negatively impacted by the lingering as well as the after-effects of the Delta variant, causing restrictive measurespandemic. One of the more pronounced after-effects for our healthcare customers involves staffing challenges such as burnout and labor shortages. The pressures associated with these challenges continue to be implemented or reinstituted, including by manyresult in delayed sales for certain of our products, particularly those that are more elective in nature. Ultimately, we believe that our product offerings are well-positioned to help our healthcare customers. Uncertainty remains regardingcustomers successfully manage issues associated with onboarding, training, developing, engaging, and retaining employees—nurses in particular—and we remain dedicated to helping our customers overcome both the extent, timing,direct and durationindirect challenges associated with the pandemic.
During the height of the pandemic, including the extent to which the availability and sustained efficacy of vaccines will positively impact public health conditions and whether potentially more contagious and/or virulent strains of the COVID-19 virus, including strains that may be resistant to currently available vaccines, may pose additional public health risks. The pandemic continues to cause uncertainty and potential economic volatility, including with regard to the pandemic’s various and unpredictable impacts on our healthcare customers and our business.
Our business is focused on providing workforce and provider solutions to healthcare organizations, and as such, the pandemic’s adverse impact on healthcare organizations has resulted in an adverse impact on our Company. Although COVID-19 did not have a significant negative impact on our revenues or net income during 2020,2021, we believe that it began to have a negative impact on our revenues during the nine months ended September 30, 2021. Additionally, certain developments related to COVID-19 have negatively impacted and are expected to continue to negatively impact our business during the remainder of 2021 and potentially thereafter. In particular, sales cycles have been delayed or postponed such that declines in sales bookings by customers during 2020 and the nine months ended September 30, 2021 will result in a negative impact to revenue and potentially to earnings during the remainder of 2021 and in 2022.
Our operating results have benefited from a temporary reduction of operating expenses related to COVID-19 conditions, but the operating expense reduction itself—despite its positive impact on operating income and adjusted EBITDA—is indicative of the negative impact the pandemic has had, and may continue to have on new bookings and renewals. We have experienced and expect to continue to experience, delayed and reduced bookings and renewals due to the pandemic. Given that we sell multiple year subscriptions to our solutions, the revenue impact of lost or delayed sales in a given period generally does not manifest until future periods, just as the revenue we recognize in a given period is generally the result of sales from a prior period. Since mid-March 2020,We believe that the delay in bookings from the height of the pandemic negatively impacted our sales organization has had limited opportunities to travel and conduct onsite sales meetings with existing or prospective customers, and we have also cancelled in-person tradeshows, which typically generate future sales opportunities. As a result, operating income and adjusted EBITDA benefitted from a $1.0 million reductionrevenue growth in operating expense related to travel restrictions during the first nine monthsquarter of 2021 compared2022, and will continue to negatively impact our revenue, at least through the second quarter of 2022 and potentially throughout the remainder of the year. However, we also experienced increased bookings in the first nine monthsquarter of 2020.
When travel restrictions lessen and travel resumes at a more normal level,2022, which we expect operating expenses associated with travelbelieve will begin to have a negative impact on operating income and EBITDA, andbenefit revenue that we do not expect revenue generated from such activities to begin offsetting such increases to operating expenses atwill recognize in the same time we incur such expenses. However, the uncertain trajectorylatter half of COVID-19 may impact when and to what extent normal operating expenses, including expenses related to sales travel and in-person tradeshows, accelerate or remain abated.2022.
We continue to closely monitor developments related to COVID-19the pandemic that may have an adverse impact on our operational and financial performance.performance and we remain prepared to the best of our ability to adjust to such developments as they may arise. We also continue to take actions focused on the safety and well-being of our employees, assisting our customers in this time of need, and mitigating operational and financial impacts to our business. We intend to continue serving our customers both in their battle to defeat the coronavirus and across the continuum of their other workforce and provider solution needs.
Additionally, to promoteWe recognize that some of the safetyuncertainties and well-being of our employees, we required our entire workforce to begin working remotely from home beginning March 16, 2020,impact that are currently being experienced in the United States on a macro-level and the entire workforce continues to work remotely to date. Although we previously intended to reopen our offices during the third quarter of 2021, due to the recent surges in COVID-19 cases as noted above, we have deferred the time at which our offices will reopen,healthcare more specifically may be both directly and are continuing to monitor local public health conditions before making a decision to reopen.
Many healthcare organizations have been, and may continue to be, substantially adversely impacted by the COVID-19 pandemic. The period of time over which this adverse impact continues, the extent to which certain healthcare organizations continue to receive and/or are eligible to utilize governmental funds as the result of federal stimulus and relief measures, and ongoing public health conditionsindirectly related to the pandemic are important factorspandemic. For example, the U.S. economy has recently experienced various disruptions, including inflationary pressures, significant disruptions to global supply networks, and challenging labor market conditions. In this regard, we have recently experienced, and believe that may impact our business.
In light of adverse developments with respect to healthcare organizations as noted above, we are continuing to monitor the ability or willingnesssome of our customers to:
|
|
|
|
|
|
We monitor our cash position and credit exposure by evaluating, among other things, weekly cash receipts, days sales outstanding (DSO), customer requests to modify payment or contract terms, and bankruptcy notices. We experienced modest improvements in DSO during the third quarter of 2021 compared to the third quarter of 2020. However, while we have not experienced any adverse impacts to customer defaults resulting from COVID-19, we are unable to know whether or to what extent negative trends related to the pandemic may arisecustomers in the future. Any deterioration in the collectability (or the timing of payments) of our accounts receivable couldhealthcare industry may adversely impact our financial results.business and results of operations. However, as discussed above, we also believe that our product offerings are well positioned to help customers mitigate some of the negative impacts otherwise associated with these challenges as we continue to fulfill our vision of improving healthcare by developing the people who provide care.
The timing of implementation of our services is also relevant to our business because our software solutions do not result in revenue recognition until they are made available for use. To the extent our customers delay or fail to implement products they have purchased, our financial results will be adversely impacted. While we have experienced a negative impact from certain implementation delays related to COVID-19, these delays have not been consistent across products or across customers. In fact, we have become more efficient in implementing certain products during the pandemic, particularly with respect to certain Workforce Solutions segment products. In contrast, our Provider Solutions business segment has, in some instances, been more sensitive to implementation delays as the result of complexities associated with implementing certain of the solutions offered through that business segment.
Conditions related to the pandemic have caused some customers to delay purchasing decisions they would have otherwise made. Such conditions also adversely impacted the ability or willingness of some customers to renew their contracts with us or to renew contracts at the same levels. Pandemic-related conditions have also delayed or otherwise adversely impacted our ability to enter into contracts with new potential customers, as some potential customers have been focused on dealing with the impact and demands that COVID-19 is having on their businesses. In addition, the limitations noted above on onsite sales meetings and in-person trade shows, as well as our customers’ ongoing uncertainties due to COVID-19 have reduced, and may continue to reduce, the ability of our sales team to make sales they otherwise would likely make but for the impact of COVID-19. As the pandemic has persisted, we have, however, continued to evolve our sales approach such that our sales representatives have been in frequent contact with customers via video conference and other remote means that do not require physical travel or onsite visits to our customers’ facilities. The timing and extent of the resumption of in-person activities will be dependent on the prevalence of future COVID-19 outbreaks, including with regard to new variants that may continue to emerge.
Given the uncertainty surrounding the adverse impacts that COVID-19 could have on our business, we took certain expense management measures in 2020 as previously disclosed. We have generally discontinued these expense management measures taking into account the improved economic environment and current conditions related to the pandemic, provided that certain expenses such as those associated with travel and tradeshows remain significantly lower than pre-pandemic levels due to limitations on our ability to engage in such activities at the same levels as prior to the pandemic. We are continuing to monitor developments related to the COVID-19 pandemic and will continue to make such expense management adjustments as we deem necessary.
Key Business Metrics
Our management utilizes the following financial and non-financial metrics in connection with managing our business.
• | Revenues, net. Revenues, net, reflect income generated by the sales of goods and services related to our operations and, prior to the adoption of ASU 2021-08 on January 1, 2022, reflects deferred revenue write-downs associated with fair value accounting for acquired businesses. Revenues, net, were |
• | Operating Income. Operating income represents the amount of profit realized from our operations and is calculated as the difference between revenues, net and operating costs and expenses. Operating income was |
• | Adjusted EBITDA. Adjusted EBITDA, calculated as set forth below under “Reconciliation of Non-GAAP Financial Measures,” is utilized by our management in connection with managing our business and provides useful information to investors because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash and non-operating |
• | hStream Subscriptions. hStream subscriptions are determined as the number of subscriptions under contract for hStream, our |
Critical Accounting Policies and Estimates
The Company’s Condensed Consolidated Financial Statements are prepared in accordance with US GAAP. These accounting principles require us to make certain estimates, judgments, and assumptions during the preparation of our Financial Statements. We believe the estimates, judgments, and assumptions upon which we rely are reasonable based upon information available to us at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the Financial Statements, as well as the reported amounts of revenues and expenses during the periods presented.presented and related disclosures. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, our Financial Statements will be affected.
The accounting policies and estimates that we believe are the most critical in fully understanding and evaluating our reported financial results include the following:
• | Revenue recognition |
• | Accounting for income taxes |
• |
|
| Goodwill |
In many cases, the accounting treatment of a particular transaction is specifically dictated by US GAAP and does not require management’s judgment in its application. There are also areas where management’s judgment in selecting among available alternatives would not produce a materially different result. See Notes to the Consolidated Financial Statements in our 20202021 Form 10-K and the Notes to the Condensed Consolidated Financial Statements herein which contain additional information regarding our accounting policies and other disclosures required by US GAAP. There have been no changes in our critical accounting policies and estimates from those reported in our 20202021 Form 10-K.
Impact on Comparability of Operating Results
The comparability of our operating results for the nine months ended September 30, 2021 to the same period for 2020 are impacted by several factors, including acquisitions, the reduction of revenues associated with legacy resuscitation products, and other non-cash items.
Between March 9, 2020 and January 19, 2021, we completed five acquisitions, which resulted in additional revenues and higher operating expenses during the three and nine months ended September 30, 2021 compared to the three and nine months ended September 30, 2020.
Our legacy agreements with Laerdal (Legacy Agreements) for the HeartCode and Resuscitation Quality Improvement (RQI) products expired pursuant to their terms on December 31, 2018. Revenues associated with sales of HeartCode and RQI products pursuant to the Legacy Agreements were significant in past years, although margins on such products were lower than HealthStream’s average margin. Revenue generated by HeartCode and RQI products pursuant to the Legacy Agreements was $9.7 million in the third quarter of 2020 compared to $0.5 million in the third quarter of 2021. For additional information, see below under “Other Developments.”
During the nine months ended September 30, 2021, the Company recorded a $1.0 million non-recurring, non-cash reduction to paid time off (PTO) expense as a result of modifications to the Company’s PTO policy. During the nine months ended September 30, 2020, the Company recorded a $3.4 million non-cash contractual adjustment that resulted in a decrease to royalty expense upon the resolution of a mutual disagreement relating to various elements of a past partnership.
Three Months Ended September 30, 2021March 31, 2022 Compared to Three Months Ended September 30, 2020March 31, 2021
Revenues, net. Revenues increased approximately $3.2$1.9 million, or 5%3%, to $64.1$65.4 million for the three months ended September 30, 2021March 31, 2022 from $60.9$63.5 million for the three months ended September 30, 2020.March 31, 2021.
A comparison of revenues by business segment is as follows (in thousands):
Three Months Ended September 30, | Three Months Ended March 31, | |||||||||||||||||||||||
Revenues by Business Segment: | 2021 | 2020 | Percentage Change | 2022 | 2021 | Percentage Change | ||||||||||||||||||
Workforce Solutions | $ | 51,155 | $ | 49,197 | 4 | % | $ | 52,039 | $ | 51,247 | 2 | % | ||||||||||||
Provider Solutions | 12,936 | 11,686 | 11 | % | 13,328 | 12,221 | 9 | % | ||||||||||||||||
Total revenues, net | $ | 64,091 | $ | 60,883 | 5 | % | $ | 65,367 | $ | 63,468 | 3 | % | ||||||||||||
% of Revenues | ||||||||||||||||||||||||
Workforce Solutions | 80 | % | 81 | % | 80 | % | 81 | % | ||||||||||||||||
Provider Solutions | 20 | % | 19 | % | 20 | % | 19 | % | ||||||||||||||||
Revenues for Workforce Solutions increased $2.0$0.8 million, or 4%2%, to $52.0 million for the three months ended March 31, 2022, from $51.2 million for the three months ended September 30, 2021 from $49.2 million for the three months ended September 30, 2020.March 31, 2021. The Workforce Solutions segment achieved this 4%2% growth while overcoming a $9.2$1.7 million decline from the legacy resuscitation business. In this regard, while revenues from legacy resuscitation products effectively ceased at the end of 2020, revenues for the three months ended September 30, 2021 included $0.5 million as we extended, with support from Laerdal, utilization of these products in 2021 for a small group of customers. Revenues from recent acquisitions and growth in other solutions more than offset the decline in legacy resuscitation revenues. Workforce revenues also benefited from a $0.5 million increase in professional services revenues, primarily associated with recently acquired businesses.
Revenues for Provider Solutions increased $1.2$1.1 million, or 11%9%, to $12.9$13.3 million for the three months ended September 30, 2021March 31, 2022, from $11.7$12.2 million for the three months ended September 30, 2020.March 31, 2021. Revenue growth was primarily attributable to new subscription revenues.
Cost of Revenues (excluding Depreciation and Amortization). Cost of revenues decreased $0.7 million, or 3%, to $22.6$22.0 million for the three months ended September 30, 2021March 31, 2022, from $23.3$22.7 million for the three months ended September 30, 2020.March 31, 2021. Cost of revenues as a percentage of revenues was 35%34% and 38%36% for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively.
Cost of revenues for Workforce Solutions decreased $0.9$1.0 million to $18.4$17.6 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period and approximated 36%34% and 39%36% of revenues for Workforce Solutions for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively. The decrease is primarily attributable to a decrease inlower royalties payable by us related to legacy resuscitation products, partially offset by increased expenses related to recent acquisitions coupledconsistent with an increasethe reduction in software expense classified as cost of revenues during the three months ended September 30, 2021.these revenues. Cost of revenues for Provider Solutions increased $0.2$0.3 million to $4.2$4.4 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period and approximated 33% and 34% of Provider Solutions revenues for both the three months ended September 30, 2021March 31, 2022 and 2020, respectively.2021. The increase in amount is primarily associated with an increase in software expense classified as cost of revenuespersonnel costs during the three months ended September 30, 2021.March 31, 2022.
Product Development. Product development expenses increased $2.1$0.9 million, or 26%9%, to $10.3$10.4 million for the three months ended September 30, 2021March 31, 2022, from $8.2$9.5 million for the three months ended September 30, 2020.March 31, 2021. Product development expenses as a percentage of revenues were 16% and 13%15% for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively.
Product development expenses for Workforce Solutions increased $2.2$0.6 million to $8.7$8.8 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period and approximated 17% and 13%16% of revenues for Workforce Solutions for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively. The increase is primarily associated with recent acquisitionsan increase in personnel costs and increased product development efforts across other workforce solutions.contract labor, which was partially offset by an increase in labor capitalized for internally developed software. Additionally, the first quarter of 2021 included a non-recurring, non-cash benefit related to the reduction of paid time off ("PTO") expense as a result of modifications to the Company's PTO policy. Product development expenses for Provider Solutions decreased $0.1increased $0.3 million to $1.6 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period and approximated 12% and 15%11% of revenues for Provider Solutions for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively. The decreaseincrease in product development expenses is primarily due to an increase in labor capitalized for internally developed software relatedpersonnel costs compared to additional product investments across the VerityStream product suite.prior year period.
Sales and Marketing. Sales and marketing expenses, including personnel costs, increased $1.3$1.4 million, or 15%16%, to $10.2$10.4 million for the three months ended September 30, 2021March 31, 2022, from $8.9$9.0 million for the three months ended September 30, 2020.March 31, 2021. Sales and marketing expenses were 16% and 15%14% of revenues for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively.
Sales and marketing expenses for Workforce Solutions increased $1.2 million to $8.2$8.4 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period and approximated 16% and 14% of revenues for Workforce Solutions for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively. The increase is primarily due to an increase in general marketing expenses and additional personnel expenses, due to recent acquisitions partially offset by lowerincreased sales commissions, associated with the decline in legacy resuscitation revenues.and higher marketing expenses. Sales and marketing expenses for Provider Solutions increased $0.1$0.2 million to $1.7$1.8 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period and approximated 13% and 14% of revenues for Provider Solutions for both the three months ended September 30, 2021March 31, 2022 and 2020, respectively.2021. The increase is due to an increase in personnel expenses and general marketing expenses. The unallocated corporate portion of sales and marketing expenses increased $70,000decreased $46,000 to $0.3$0.2 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period.
Other General and Administrative Expenses. Other general and administrative expenses was $10.0decreased $0.5 million, or 6%, to $9.2 million for both the three months ended September 30, 2021 and September 30, 2020.March 31, 2022, from $9.7 million for the three months ended March 31, 2021. Other general and administrative expenses were 16%14% and 15% of revenues for both the three months ended September 30,March 31, 2022 and 2021, and 2020.respectively.
Other general and administrative expenses for Workforce Solutions decreased $0.5$1.0 million to $2.9$2.1 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period and approximated 6%4% and 7%6% of Workforce Solutions revenues for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively. The decrease is primarily due to a decreaselower transition service costs associated with prior acquisitions and reductions in software expense classified as general and administrative expenses partially offset by expenses related to recent acquisitions.facilities costs associated with closing certain leased satellite offices. Other general and administrative expenses for Provider Solutions increased $0.1 million$45,000 to $1.0$0.9 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period and approximated 8% and 7% of Provider Solutions revenues for both the three months ended September 30, 2021March 31, 2022 and 2020, respectively. The increase is primarily due to increased personnel costs compared to the prior year period.2021. The unallocated corporate portion of other general and administrative expenses increased $0.4 million to $6.1$6.2 million for the three months ended September 30, 2021March 31, 2022, compared to the prior year period primarily due to increased personnel costs.costs and employee recruitment expenses.
Depreciation and Amortization. Depreciation and amortization expense increased $1.7$0.1 million, or 23%2%, to $9.1$9.3 million for the three months ended September 30, 2021March 31, 2022, from $7.4$9.2 million for the three months ended September 30, 2020.March 31, 2021. This increase is primarily a result of increases toan increase in amortization associated with capitalized software and intangible assets from recent acquisitions.software.
Other (Loss) Income,Loss, Net. Other (loss) income,loss, net was a loss of $99,000$0.3 million for the three months ended September 30, 2021March 31, 2022, compared to income of $0.1 million for the three months ended September 30, 2020.March 31, 2021. The decrease is primarily a result of lower interest income due to reductions in cash and investment balances and lower interest rate yields duringa greater loss from equity method investments for the three months ended September 30, 2021March 31, 2022, compared to the prior year period.
Income Tax Provision. The Company recorded a provision for income taxes of $0.2$0.9 million for both the three months ended September 30, 2021 compared to $0.6 million for the three months ended September 30, 2020.March 31, 2022 and 2021. The Company’s effective tax rate was 11%23% for the three months ended September 30, 2021March 31, 2022, compared to 19%29% for the three months ended September 30, 2020.March 31, 2021. The Company’s effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, foreign income taxes, the effect of various permanent tax differences, and recognition of discrete tax items. During the three months ended March 31, 2022, the Company recorded discrete tax expense of $0.1 million, which consisted primarily of tax deficiencies associated with stock-based awards. During the three months ended March 31, 2021, the Company recorded discrete tax expense a $0.1 million related primarily to a permanent difference related to purchase accounting adjustments and the impact of a state tax rate change enacted during the period.
Net Income. Net income was approximately $1.5$2.9 million and $2.6$2.3 million for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively. Earnings per share (EPS) was $0.05$0.09 per share (diluted) and $0.08$0.07 per share (diluted) for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively.
Adjusted EBITDA was $12.5$14.0 million for the three months ended September 30, 2021March 31, 2022, compared to $11.2$13.6 million for the three months ended September 30, 2020.March 31, 2021. See “Reconciliation of Non-GAAP Financial Measures” below for our reconciliation of adjusted EBITDA to the most directly comparable measures under US GAAP and disclosure regarding why we believe Adjustedadjusted EBITDA provides useful information to investors.
Nine Months Ended September 30, 2021 Compared to Nine Months Ended September 30, 2020
Revenues, net. Revenues increased $9.4 million, or 5%, to $192.4 million for the nine months ended September 30, 2021 from $183.0 million for the nine months ended September 30, 2020.
A comparison of revenues by business segment is as follows (in thousands):
Nine Months Ended September 30, | ||||||||||||
Revenues by Business Segment: | 2021 | 2020 | Percentage Change | |||||||||
Workforce Solutions | $ | 154,559 | $ | 147,909 | 4 | % | ||||||
Provider Solutions | 37,815 | 35,099 | 8 | % | ||||||||
Total revenues, net | $ | 192,374 | $ | 183,008 | 5 | % | ||||||
% of Revenues | ||||||||||||
Workforce Solutions | 80 | % | 81 | % | ||||||||
Provider Solutions | 20 | % | 19 | % | ||||||||
Revenues for Workforce Solutions increased $6.7 million, or 4%, over the first nine months of 2020. Contributions from recent acquisitions and growth in other workforce solutions more than offset the expected decline in revenues from legacy resuscitation products of $28.3 million. While revenues from legacy resuscitation products effectively ceased at the end of 2020, revenues for the nine months ended September 30, 2021 included $3.2 million as we extended, with support from Laerdal, utilization of these products into 2021 for a small group of customers. Workforce revenues also benefited from a $1.4 million increase in professional services revenues, primarily associated with recently acquired businesses.
Revenues for Provider Solutions increased $2.7 million, or 8%, over the first nine months of 2020. Revenue growth was primarily attributable to new subscription revenues.
Cost of Revenues (excluding depreciation and amortization). Cost of revenues increased $1.5 million, or 2%, to $68.1 million for the nine months ended September 30, 2021 from $66.6 million for the nine months ended September 30, 2020. Cost of revenues as a percentage of revenues was 35% and 36% for the nine months ended September 30, 2021 and 2020, respectively. Cost of revenues were favorably impacted by $0.2 million during the nine months ended September 30, 2021, resulting from the non-cash reduction to PTO expense, and were favorably impacted in the amount of $3.4 million during the nine months ended September 30, 2020 from the one-time non-cash contractual adjustment to royalty expense.
Cost of revenues for Workforce Solutions increased $1.2 million to $55.9 million and approximated 36% and 37% of revenues for Workforce Solutions for the nine months ended September 30, 2021 and 2020, respectively. The increase in amount is primarily associated with increased expenses related to recent acquisitions, the one-time contractual adjustment to cost of revenues in the amount of $3.4 million recorded during the nine months ended September 30, 2020, and an increase in software expense classified as cost of revenues during the nine months ended September 30, 2021, partially offset by a decline in royalties related to legacy resuscitation products. Cost of revenues for Provider Solutions increased $0.3 million to $12.1 million and approximated 32% and 34% of Provider Solutions revenues for the nine months ended September 30, 2021 and 2020, respectively. The increase in amount is primarily associated with an increase in software expense classified as cost of revenues during the nine months ended September 30, 2021.
Product Development. Product development expenses increased $6.7 million, or 29%, to $30.2 million for the nine months ended September 30, 2021 from $23.5 million for the nine months ended September 30, 2020. Product development expenses as a percentage of revenues were 16% and 13% of revenues for the nine months ended September 30, 2021 and 2020, respectively. Product development expenses were favorably impacted in the amount of $0.4 million during the nine months ended September 30, 2021 from the non-cash reduction to PTO expense.
Product development expenses for Workforce Solutions increased $7.3 million to $25.8 million and approximated 17% and 13% of revenues for Workforce Solutions for the nine months ended September 30, 2021 and 2020, respectively. The increase in amount is primarily associated with recent acquisitions and increased product development efforts across other workforce solutions. Product development expenses for Provider Solutions decreased $0.6 million to $4.4 million and approximated 12% and 14% of revenues for Provider Solutions for the nine months ended September 30, 2021 and 2020, respectively. The decrease is primarily due to an increase in labor capitalized for internally developed software related to additional product investments across the VerityStream product suite.
Sales and Marketing. Sales and marketing expenses, including personnel costs, increased $2.4 million, or 9%, to $28.7 million for the nine months ended September 30, 2021 from $26.3 million for the nine months ended September 30, 2020. Sales and marketing expenses were 15% and 14% of revenues for the nine months ended September 30, 2021 and 2020, respectively. Sales and marketing expenses were favorably impacted by $0.2 million during the nine months ended September 30, 2021 resulting from the non-cash reduction to PTO expense.
Sales and marketing expenses for Workforce Solutions increased $2.1 million to $22.9 million and approximated 15% and 14% of revenues for Workforce Solutions for the nine months ended September 30, 2021 and 2020, respectively. The increase is primarily associated with increases in general marketing expenses and recent acquisitions, partially offset by lower sales commissions associated with the decline in legacy resuscitation revenues and decreases in travel expenses as a result of the COVID-19 pandemic. Sales and marketing expenses for Provider Solutions increased $0.1 million to $4.9 million and approximated 13% of revenues for Provider Solutions for both the nine months ended September 30, 2021 and 2020. The unallocated portion of sales and marketing expenses increased $0.2 million to $1.0 million compared to the prior year period.
Other General and Administrative Expenses. Other general and administrative expenses decreased $0.5 million, or 2%, to $29.4 million for the nine months ended September 30, 2021 from $29.9 million for the nine months ended September 30, 2020. Other general and administrative expenses as a percentage of revenues were 15% and 16% of revenues for the nine months ended September 30, 2021 and 2020, respectively. Other general and administrative expenses were favorably impacted by $0.2 million during the nine months ended September 30, 2021 resulting from the non-cash reduction to PTO expense.
Other general and administrative expenses for Workforce Solutions decreased $2.3 million to $9.0 million and approximated 6% and 8% of revenues for Workforce Solutions for the nine months ended September 30, 2021 and 2020, respectively. The decrease is primarily associated with a decrease in software expense classified as general and administrative expenses during the nine months ended September 30, 2021, partially offset by expenses associated with recent acquisitions. Other general and administrative expenses for Provider Solutions increased $0.2 million to $2.7 million and approximated 7% of revenues for Provider Solutions for both the nine months ended September 30, 2021 and 2020. The unallocated corporate portion of other general and administrative expenses increased $1.6 million to $17.8 million compared to the first nine months of 2020 primarily due to increased personnel expenses over the prior year period.
Depreciation and Amortization. Depreciation and amortization increased $5.4 million, or 25%, to $27.4 million for the nine months ended September 30, 2021 from $22.0 million for the nine months ended September 30, 2020. The increase resulted from increases in amortization associated with capitalized software and intangible assets from recent acquisitions.
Other (Loss) Income, Net. Other (loss) income, net was a loss of $0.3 million for the nine months ended September 30, 2021 compared to income of $2.0 million for the nine months ended September 30, 2020. This decrease is driven by the $1.2 million gain associated with the change in fair value of the non-marketable equity investment in NurseGrid prior to the acquisition of NurseGrid on March 9, 2020, coupled with lower interest income due to reductions in bond yields and bank interest rates during the nine months ended September 30, 2021 compared to the prior year period.
Income Tax Provision. The Company recorded a provision for income taxes of $2.0 million and $3.5 million for the nine months ended September 30, 2021 and 2020, respectively. The Company’s effective tax rate was 25% for the nine months ended September 30, 2021 compared to 21% for the nine months ended September 30, 2020. The Company’s effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, foreign income taxes, and the effect of various permanent tax differences. During the nine months ended September 30, 2021, the Company recorded discrete tax expense of $0.2 million, which included purchase accounting adjustments, changes in state tax rates enacted during the period, and lower research and development tax credits recognized than previously estimated. During the nine months ended September 30, 2020, the Company recorded a $1.2 million change in fair value of non-marketable equity investments as a result of the NurseGrid acquisition, which is not a taxable transaction, resulting in a tax benefit of $0.3 million, and recognized tax benefits resulting from higher research and development tax credits than previously estimated.
Net Income. Net income was $6.2 million for the nine months ended September 30, 2021 compared to $13.2 million for the nine months ended September 30, 2020. Earnings per diluted share were $0.20 and $0.41 per share for the nine months ended September 30, 2021 and 2020, respectively.
Adjusted EBITDA increased $5.4 million to $40.6 million for the nine months ended September 30, 2021 compared to $35.2 million for the nine months ended September 30, 2020. This increase resulted from the factors mentioned above. See “Reconciliation of Non-GAAP Financial Measures” below for our reconciliation of Adjusted EBITDA to the most directly comparable measure under US GAAP.
Other Developments
Our legacy agreements with Laerdal (Legacy Agreements) for the HeartCode and Resuscitation Quality Improvement (RQI) products expired pursuant to their terms on December 31, 2018. Revenues associated with sales of HeartCode and RQI products pursuant to the Legacy Agreements were significant in recent years, although margins on such products have been lower than HealthStream’s average margin. Revenue generated by HeartCode and RQI products pursuant to the Legacy Agreements was $38.4 million and $58.9 million in 2020 and 2019, respectively. While revenues from legacy resuscitation products effectively ceased at the end of 2020, revenues for the nine months ended September 30, 2021 included $3.2 million as we extended, with Laerdal’s support, utilization of these products for a small group of customers. We expect revenue from legacy products to be de minimis for the fourth quarter of 2021.
On December 6, 2018, we announced a new agreement with RQI Partners, a joint venture between Laerdal and the American Heart Association. This agreement with RQI Partners was not an extension or renewal of the expired Legacy Agreements with Laerdal and should not be construed as such. Under our agreement with RQI Partners, HealthStream will neither market nor sell HeartCode or RQI. Our RQI Partners agreement provides for continuity of service for customers that desire to purchase HeartCode or RQI from RQI Partners after December 31, 2018 and receive it via the HealthStream Learning Center. RQI Partners will remit a fee to us when sales of HeartCode and RQI are delivered via the HealthStream Learning Center. These fees will not be sufficient to supplant the revenue runout associated with the Legacy Agreements.
We remain actively engaged in efforts to broaden the scope and utilization of our simulation-related offerings to include a range of clinical competencies that extend beyond resuscitation, and we intend to bring to market a broadened scope of simulation-based offerings, including resuscitation programs. On January 17, 2019, as part of a seven-year collaboration agreement with the American Red Cross which spans to 2026, we announced the launch of the American Red Cross Resuscitation Suite. We are actively engaged in efforts to market, sell, and deliver our new resuscitation offering, which includes the American Red Cross Resuscitation Suite and validation of skills through a technology enabled Innosonian manikin. A growing number of customers have been implemented on our new resuscitation offering and the solution continues to gain acceptance in the market. We believe our efforts to market, sell, and deliver the American Red Cross Resuscitation Suite, along with efforts to bring additional simulation-related offerings to market, are giving rise to additional and higher margin opportunities than those that existed under the Legacy Agreements.
Reconciliation of Non-GAAP Financial Measures
This Quarterly Report on Form 10-Q presents adjusted EBITDA, which is a non-GAAP financial measure used by management in analyzing our financial results and ongoing operational performance.
In order to better assess the Company’s financial results, management believes that net income excluding the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses (as discussed in greater detail below) and before interest, income taxes, stock basedstock-based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, and the de-recognition of non-cash expense resulting from the paid time off expense reduction in the first quarter of 2021 and the resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to cost of sales in the first quarter of 2020 (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash and non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. We also believe that adjusted EBITDA is useful to many investors to assess the Company’s ongoing operating performance and to compare the Company’s operating performance between periods. Additionally, beginning in 2021, executiveshort-term cash incentive bonuses and certain performance-based equity awards are based on the achievement of adjusted EBITDA (as defined in applicable bonus and equity grant documentation) targets.
As noted above, the definition of adjusted EBITDA includes an adjustment for the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses. FollowingPrior to the Company early adopting ASU 2021-08 effective January 1, 2022, following the completion of any acquisition by the Company, the Company mustwas required to record the acquired deferred revenue at fair value as defined in GAAP, which may resulttypically resulted in a write-down of the acquired deferred revenue. IfWhen the Company iswas required to record a write-down of deferred revenue, it may resultresulted in lower recognized revenue, operating income, and net income in subsequent periods. Revenue for any such acquired business iswas deferred and iswas typically recognized over a one-to-two year period following the completion of any particular acquisition, so our GAAP revenues for this one-to-two year period willwould not reflect the full amount of revenues that would have been reported if the acquired deferred revenue was not written down to fair value. Management believes that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred write-downs associated with fair value accounting for businesses acquired businessesprior to the January 1, 2022 effective date of the Company's adoption of ASU 2021-08 provides useful information to investors because the deferred revenue write-down recognized in periods after an acquisition may, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance and thus adjusting for this amount may assist in comparing the Company’s results of operations between periods. Following the adoption of ASU 2021-08, contracts acquired in an acquisition completed on or after January 1, 2022 will be measured as if the Company had originated the contract (rather than the contract being measured at fair value) such that, for such acquisitions, the Company will no longer record deferred revenue write-downs associated with acquired businesses (for acquisitions completed prior to January 1, 2022, the Company will continue to record deferred revenue write-downs associated with fair value accounting for periods on and after January 1, 2022 consistent with past practice). At the current time, the Company intends to continue to include an adjustment in the definition of adjusted EBITDA for the impact of deferred revenue write-downs from business acquired prior to January 1, 2022 given the ongoing impact of such deferred revenue on our financial results.
Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and has limitations as analytical tools.
A reconciliation of adjusted EBITDA to the most directly comparable GAAP measure is set forth below (in thousands).
Three Months Ended September 30, | Nine Months Ended September 30, | Three Months Ended March 31, | ||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | 2022 | 2021 | |||||||||||||||||||
GAAP net income | $ | 1,500 | $ | 2,634 | $ | 6,232 | $ | 13,168 | $ | 2,893 | $ | 2,291 | ||||||||||||
Deferred revenue write-down | 805 | 75 | 3,657 | 355 | 94 | 1,622 | ||||||||||||||||||
Interest income | (24 | ) | (88 | ) | (64 | ) | (919 | ) | (15 | ) | (18 | ) | ||||||||||||
Interest expense | 33 | 26 | 99 | 76 | 32 | 32 | ||||||||||||||||||
Income tax provision | 186 | 600 | 2,033 | 3,519 | 866 | 922 | ||||||||||||||||||
Stock based compensation expense | 861 | 557 | 2,260 | 1,665 | ||||||||||||||||||||
Stock-based compensation expense | 774 | 616 | ||||||||||||||||||||||
Depreciation and amortization | 9,141 | 7,406 | 27,443 | 22,005 | 9,322 | 9,153 | ||||||||||||||||||
Non-cash paid time off expense | — | — | (1,011 | ) | — | — | (1,011 | ) | ||||||||||||||||
Change in fair value of non-marketable equity investments | — | — | — | (1,181 | ) | |||||||||||||||||||
Non-cash royalty expense | — | — | — | (3,440 | ) | |||||||||||||||||||
Adjusted EBITDA | $ | 12,502 | $ | 11,210 | $ | 40,649 | $ | 35,248 | $ | 13,966 | $ | 13,607 | ||||||||||||
Liquidity and Capital Resources
Net cash provided by operating activities increased by $5.6$1.6 million to $36.4$20.7 million during the ninethree months ended September 30, 2021March 31, 2022, from $30.8$19.1 million during the ninethree months ended September 30, 2020.March 31, 2021. Such increase was primarily drivendue to lower royalties paid by higherus compared to the prior year period and was partially offset by lower cash collections.receipts and increased labor costs. Our DSO was 4045 days for the thirdfirst quarter of 20212022 compared to 4352 days for the thirdfirst quarter of 2020.2021. The Company calculates DSO by dividing the average accounts receivable balance for the quarter by average daily revenues for the quarter. The Company’s primary sources of cash were receipts generated from the sales of our products and services. The primary uses of cash to fund operations included personnel expenses, sales commissions, royalty payments, payments for contract labor and other direct expenses associated with delivery of our products and services, and general corporate expenses.
Net cash used in investing activities was $17.0$4.0 million for the ninethree months ended September 30, 2021March 31, 2022, compared to $38.5$9.7 million for the ninethree months ended September 30, 2020.March 31, 2021. During the ninethree months ended September 30,March 31, 2022, the Company spent $22,000 related to a post-closing adjustment for a prior acquisition, invested in marketable securities of $2.0 million, made payments for capitalized software development of $6.3 million, and purchased property and equipment of $0.6 million. These uses of cash were partially offset by $5.0 million in maturities of marketable securities. During the three months ended March 31, 2021, the Company spent $2.0 million to acquire ComplyALIGN and on a net cash basis received $1.3 million of proceeds upon settling post-closing adjustments related to ANSOS and ShiftWizard acquisitions for a net cash outflow of $0.7 million onfor business combinations, invested in marketable securities of $5.2 million, made payments for capitalized software development of $16.6$5.3 million, purchased property and equipment of $2.6$2.0 million, and invested $1.8 million in equity method investments. These uses of cash were partially offset by $9.9 million in maturities of marketable securities. During the nine months ended September 30, 2020 the Company paid $21.4 million on business combinations, invested in marketable securities of $61.2 million, made payments for capitalized software development of $12.4 million, purchased property and equipment of $1.7 million, and invested $1.3$1.0 million in non-marketable equity investments. These uses of cash were partially offset by $59.5$4.5 million in maturities of marketable securities.
Net cash used in financing activities was approximately $0.5$20.2 million for the ninethree months ended September 30, 2021March 31, 2022, compared to $16.8$0.4 million for the ninethree months ended September 30, 2020.March 31, 2021. The useuses of cash for the ninethree months ended September 30, 2021March 31, 2022 included $19.7 million for repurchases of common stock and $0.5 million for the payment of employee payroll taxes in relation to the vesting of restricted share units. The uses of cash for the ninethree months ended September 30, 2020March 31, 2021 primarily included $16.4 million for common stock repurchases and $0.4 million for the payment of employee payroll taxes in relation to the vesting of restricted share units.
Our balance sheet reflects negative working capital of $7.3 million at March 31, 2022, compared to positive working capital of $10.3 million at September 30, 2021 compared to negative working capital of $4.7$6.5 million at December 31, 2020.2021. The improvementdecrease in working capital is primarily a result of stronga reduction in cash collections duringto fund the first nine monthsrepurchases of 2021.common stock and an increase in deferred revenue. The Company’s primary source of liquidity as of September 30, 2021March 31, 2022 was $55.5$43.4 million of cash and cash equivalents and $5.1$2.0 million of marketable securities. The Company also has a $65.0 million revolving credit facility, all of which was available for additional borrowing at September 30, 2021.March 31, 2022. The revolving credit facility expires on October 28, 2023, unless earlier renewed or amended.
On November 30, 2021, the Company's Board of Directors authorized a share repurchase program to repurchase up to $20.0 million of the Company's outstanding shares of common stock. The share repurchase program concluded on March 8, 2022, when the maximum dollar amount authorized under the program was expended. Under this program, the Company repurchased a total of 853,023 shares in open market purchases at an aggregate value of $20.0 million, reflecting an average price per share of $23.45 (excluding the cost of broker commissions). During the three months ended March 31, 2022, the Company repurchased 649,739 shares pursuant to this share repurchase program at an aggregate fair value of $14.9 million, based on an average price per share of $22.92 (excluding the cost of broker commissions).
On March 14, 2022, the Company's Board of Directors approved an expansion of the Company's share repurchase program by authorizing the repurchase of up to an additional $10.0 million of the Company's outstanding shares of common stock. The share repurchase program will terminate on the earlier of March 13, 2023, or when the maximum dollar amount has been expended. During the three months ended March 31, 2022, the Company repurchased 242,647 shares pursuant to this share repurchase program at an aggregate fair value of $5.0 million, based on an average price per share of $20.52 (excluding the cost of broker commissions).
We believe that our existing cash and cash equivalents, marketable securities, cash generated from operations, and available borrowings under our revolving credit facility will be sufficient to meet anticipated working capital needs, new product development, and capital expenditures for at least the next 12 months.months and for the foreseeable future thereafter.
In addition, the Company’s growth strategy includes acquiring businesses or making strategic investments in businesses that complement or enhance our business. It is anticipated that future acquisitions or strategic investments, if any, would be effected through cash consideration, stock consideration, or a combination of both. The issuance of our stock as consideration for an acquisition or to raise additional capital could have a dilutive effect on earnings per share and could adversely affect our stock price. Our revolving credit facility contains financial covenants and availability calculations designed to set a maximum leverage ratio of outstanding debt to adjusted EBITDA and an interest coverage ratio of adjusted EBITDA to interest expense. Therefore, the maximum borrowings against our revolving credit facility would be dependent on the covenant calculations at the time of borrowing. As of September 30, 2021,March 31, 2022, we were in compliance with all covenants. There can be no assurance that amounts available for borrowing under our revolving credit facility will be sufficient to consummate any possible acquisitions, and we cannot assure you that if we need additional financing that it will be available on terms favorable to us, or at all. Failure to generate sufficient cash flow from operations or raise additional capital when required in sufficient amounts and on terms acceptable to us could harm our business, financial condition, and results of operations.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
The Company is exposed to market risk from changes in interest rates, foreign currency risk, and investment risk. We do not have any commodity price risk.
Interest Rate Risk
As of September 30, 2021March 31, 2022, and during the three months then ended, the Company had no outstanding debt. We may become subject to interest rate market risk associated with any future borrowings under our revolving credit facility. The interest rate under the revolving credit facility varies depending on the interest rate option selected by the Company plus a margin determined in accordance with a pricing grid. We are also exposed to market risk with respect to our cash and investment balances, which approximated $60.6$45.4 million at September 30, 2021.March 31, 2022. Assuming a hypothetical 10% decrease in interest rates for invested balances, interest income from cash and investments would decrease on an annualized basis by approximately $10,000.$5,000.
Foreign Currency Risk
We have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the US dollar, including Canadian dollar, New Zealand dollar, and Australian dollar. Increases or decreases in our foreign-denominated revenue from movements in foreign exchange rates are often partially offset by the corresponding increases or decreases in our foreign-denominated operating expenses.
To the extent that our international operations grow, our risks associated with fluctuation in currency rates will become greater, and we will continue to assess our approach to managing this risk. In addition, currency fluctuations or a weakening US dollar can increase the costs of our international operations. To date, we have not entered into any foreign currency hedging contracts although we may do so in the future.
Investment Risk
The Company’s investment policy and strategy is focused on investing in highly rated securities with the objective of minimizing the potential risk of principal loss. The Company’s policy limits the amount of credit exposure to any single issuer and sets limits on the average portfolio maturity.
We have an investment portfolio that includes strategic investments in privately held companies, which primarily include early-stage companies. We primarily invest in healthcare technology companies that we believe can help expand our ecosystem. We may continue to make these types of strategic investments as opportunities arise that we find attractive. We may experience additional volatility to our Consolidated Financial Statements due to changes in market prices, observable price changes, and impairments to our strategic investments. These changes could be material based on market conditions and events.
The above market risk discussion and the estimated amounts presented are forward-looking statements of market risk assuming the occurrence of certain adverse market conditions. Actual results in the future may differ materially from those projected as a result of actual developments in the market.
Item 4. Controls and Procedures
Evaluation of Controls and Procedures
HealthStream’s chief executive officer and principal financial officer have reviewed and evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report. Based on that evaluation, the chief executive officer and principal financial officer have concluded that HealthStream’s disclosure controls and procedures were effective to ensure that the information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and the information required to be disclosed in the reports the Company files or submits under the Exchange Act was accumulated and communicated to the Company’s management, including its chief executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in HealthStream’s internal control over financial reporting that occurred during the thirdfirst quarter of 20212022 that has materially affected, or that is reasonably likely to materially affect, HealthStream’s internal control over financial reporting.
There have been no material changes to the risk factors previously disclosed in the 20202021 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On November 30, 2021, the Company announced a share repurchase program approved by the Company's Board of Directors under which the Company was authorized to purchase up to $20.0 million of its common stock. Under this program, during the first three months of 2022 the Company repurchased 649,739 shares at an aggregate fair value of $14.9 million, reflecting an average price per share of $22.92 (excluding the cost of broker commissions). The share repurchase program concluded on March 8, 2022, when the maximum dollar amount was expended.
On March 14, 2022, the Company announced an expansion of the share repurchase program authorized by the Company’s Board of Directors under which the Company may purchase up to an additional $10.0 million of its common stock. Pursuant to this authorization, repurchases may be made in the open market, including under a Rule 105b-1 plan, through privately negotiated transactions, or otherwise. Under this program, during the first three months of 2022 the Company repurchased 242,647 shares at an aggregate fair value of $5.0 million, reflecting an average price per share of $20.52 (excluding the cost of broker commissions). In addition, any future repurchases under the authorization will be subject to prevailing market conditions, liquidity and cash flow considerations, applicable securities laws requirements (including under Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as applicable), and other factors. The share repurchase program will terminate on the earlier of March 13, 2023 or when the maximum dollar amount has been expended.
The table below sets forth activity under the stock repurchase plans for the three months ended March 31, 2022.
Period | (a) Total number of shares (or units) purchased | (b) Average price paid per share (or unit)(1) | (c) Total number of shares (or units) purchased as part of publicly announced plans or programs | (d) Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs | ||||||||||||
Month #1 (January 1 - 31) | 216,645 | $ | 25.17 | 216,645 | $ | 9,438,062 | ||||||||||
Month #2 (February 1 - February 28) | 282,247 | 22.36 | 282,247 | 3,127,204 | ||||||||||||
Month #3 (March 1 - March 31) | 393,494 | 20.60 | 393,494 | 5,020,204 | ||||||||||||
Total | 892,386 | $ | 22.27 | 892,386 | $ | 5,020,204 | ||||||||||
(1) | The weighted average price paid per share of common stock does not include the cost of broker commissions. |
(a) | Exhibits |
| 10.1^ | HealthStream, Inc. 2022 Cash Incentive Bonus Plan |
| 10.2^ | Form of HealthStream, Inc. Restricted Share Unit Agreement (Performance) under 2016 Omnibus Incentive Plan |
| 10.3^ | Form of HealthStream, Inc. Restricted Share Unit Agreement (Performance) contingent upon approval of 2022 Omnibus Incentive Plan |
| 10.4^ | Form of HealthStream, Inc. Restricted Share Unit Agreement (Time Based) contingent upon approval of 2022 Omnibus Incentive Plan |
31.1 | |
31.2 | |
32.1 | |
32.2 | |
101.1 INS | Inline XBRL Instance Document – The instant document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
101.1 SCH | Inline XBRL Taxonomy Extension Schema |
101.1 CAL | Inline XBRL Taxonomy Extension Calculation Linkbase |
101.1 DEF | Inline XBRL Taxonomy Extension Definition Linkbase |
101.1 LAB | Inline XBRL Taxonomy Extension Label Linkbase |
101.1 PRE | Inline XBRL Taxonomy Extension Presentation Linkbase |
104 | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended | |
| ^ | Management contract of compensatory plan or arrangement |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HEALTHSTREAM, INC. | |||
| By: | /s/ Scott A. Roberts | |
Scott A. Roberts | |||
Chief Financial Officer | |||